Introduction {#Sec1}
============

*Stephania tetrandra* S. Moore (*S. tetrandra*) is a traditional medicine used in China, Japan and South Korea. *S. tetrandra* is a perennial liana of the genus *Stephania*, belonging to the Menispermaceae family. The official name of *S. tetrandra* is "Fen Fang Ji" in Chinese. "Fang Ji" or "Han Fang Ji" or "Guang Fang Ji" or "Mu Fang Ji" in Chinese is also usually used as the folk name of *S. tetrandra*. However, *Aristolochia fangchi* Y.C. Wu ex L.D. Chow & S.M. Hwang (*A. fangchi*) (Aristolochiaceae) and *Aristolochia heterophyla* Hemsl (*A. heterophyla*) (Aristolochiaceae) are two separate species also used in traditional Chinese medicine (TCM) that are also called "Fang ji", which can cause confusion. *A. fangchi* and *A. heterophyla* contain high concentrations of aristolochic acids that can result in nephrotoxicity. When used medicinally, the morphological similarities between the two roots pose a potential identification problem that may result in accidental substitution (Tankeu et al. [@CR227]). Thus, a comprehensive reference of available information on *S. tetrandra* would prevent confusion in its usage.

*S. tetrandra* is principally used in TCM as a diuretic, anti-inflammatory and an antirheumatic treatment (Joshi et al. [@CR101]; Chinese Pharmacopoeia Commission [@CR38]; Jiangsu New Medical College [@CR100]; Chinese Botany Editorial Committee [@CR37]). Over the previous three decades, extensive chemical analysis and modern activity evaluation have been conducted because its traditional uses are of interest to researchers. To date, phytochemical studies have identified a total of 67 alkaloids, two bisflavones, two phytosterols and n-pentatriacontane from the roots and aerial parts of *S. tetrandra.*

The use of herbal medicines has gained popularity worldwide due to their long history of traditional use, their cost-effectiveness, accessibility and reportedly lower incidence of adverse effects (Mullaicharam [@CR176]). Yet now the phrase "Chinese-herb nephropathy" has recently attracted attention because the aristolochic acid present in a number of TCMs can cause nephropathy (Nortier et al. [@CR180]; Meyer et al. [@CR173]; Okada [@CR182]). "Yao Xing Lun" is an ancient TCM book from the Tang Dynasty of China that reported that "Fang Ji" had "little toxicity". Although other ancient TCM books have labeled "Fang Ji" as non-toxic, it is not suitable for long-term use in large doses. In fact, there are published reports that *S. tetrandra* has toxic effects in the kidneys and liver (Liang et al. [@CR141]). It has not yet been established whether the "little toxicity" is a result of aristolochic acids or the other constituents in *S. tetrandra*. To fully evaluate this traditional medicine, it is important to systematically review its traditional uses, phytochemistry, pharmacological properties, and toxicity. This will assist in establishing the profile of therapeutic and adverse clinical effects.

Ethnobotany of *S. tetrandra* {#Sec2}
=============================

Botany {#Sec3}
------

*S. tetrandra* is a perennial herbaceous liana of the subgenus Botryodiscia of the genus *Stephania* and a member of the Menispermaceae family. According to "The Plant List" ([www.theplantlist.org](http://www.theplantlist.org)), *Stephania tetrandra* S. Moore (*S. tetrandra*) is the only accepted name for the plant, and no synonyms have been reported for it.

*S. tetrandra* grows to a height of 1--3 m with a root that is fleshy and cylindrical. It has a long cylindrical stem that is straight and voluminous. The leaves are triangular in nature with a convex tip and a petiole that is 3--7 cm in length (Fig. [1](#Fig1){ref-type="fig"}). Its inflorescence consists of yellow-white flowers that form a capitulum between May and June, with staminate flowers that are radially symmetrical. The fruit is red and nearly spherical, ripening between July and September (Jiangsu New Medical College [@CR100]; Chinese Botany Editorial Committee [@CR37]; Feng et al. [@CR60]; Luo [@CR159]; Xie [@CR266]).Fig. 1*Stephania tetrandra*: **a** and **b** stem, flower and leaf, and **c** a longitudinal section of the roots

*S. tetrandra* grows on hillsides, foothills and the edges of grasslands and shrublands. In China, it is principally found in the provinces of Zhejiang, Anhui, Fujian, Taiwan, Hunan, Jiangxi, Guangxi, Guangdong and Hainan. Although the plant is robust, it has a slow growth cycle. Three years of growth are required before the roots of *S. tetrandra* can be used for medicinal purposes (Jiangsu New Medical College [@CR100]; Chinese Botany Editorial Committee [@CR37]; Zhu et al. [@CR320]; Xie [@CR266]). Currently, the majority of *S. tetrandra* used for medicinal purposes are wild-growing rather than cultivated.

Traditional use {#Sec4}
---------------

"Fang Ji\" was firstly recorded as medicine in an ancient Chinese medicinal book of \"Shen Nong Ben Cao Jing\" during the Han Dynasty (Huang et al. [@CR90]). However, "Fang Ji" could refer to *Aristolochia heterophyla* Hemsl ("Hang Fang Ji") *or Cocculus trilobus* (L.) DC ("Mu Fang Ji") in ancient China (Huang et al. [@CR90]; Hu [@CR82]). Although "Fang Ji" used as traditional Chinese medicine over a thousand year, the medicinal history of *S. tetrandra* is few hundreds years (Huang et al. [@CR90]; Hu [@CR82]). Huang *et al*. speculated that *S. tetrandra* used as "Fang Ji" medicine in Ming Dynast for the first time (Huang et al. [@CR90]), but the study of Chen *et al*. investigated that *S. tetrandra* was the main medicinal plant source of "Fang Ji" in the Republic China period (Chen [@CR36]). Anyhow, *S. tetrandra* is officiallized as "Fangji" by the authoritative Chinese medicine book, "Pharmacopoeia of People's Republic of China, 2015 version".

The medicinal component of "Fang Ji" is its root, which was firstly recorded in the ancient Chinese book "Sheng Nong Ben Cao Jing" written during the Han Dynasty. A number of ancient Chinese medicinal books from Han Dynasty to Qing Dynasty, such as "Min Yi Bie Lu", "Ben Cao Gang Mu", "Ben Cao Cong Xin", recorded that "Fang Ji" was suitable as a treatment for "wind-cold", "wind-swelling", treats warm malaria, edema, typhoid fever and stroke, acts as a diuretic, and so on.

To summarize, "Fang Ji" has been used in China as a folk remedy for arthralgia associated with rheumatoid arthritis, wet beriberi, dysuria, eczema and inflamed sores (Jiangsu New Medical College [@CR100]). Nevertheless, different species resulted in different traditional medicinal effects. "Fang Ji" could refer to "Han Fang Ji" or "Mu Fang Ji" before Ming and Qing Dynasty. Afterwards, "Fang Ji" could also refer to "Han Fang Ji" or "Mu Fang Ji" or "Feng Fang Ji" or "Guang Fang Ji". As recored in two ancient Chinese medicinal books "Ben Cao Meng Quan" and "Ben Cao Shi Yi", "Mu" was used for the treatment of "Wind", such as "wind-cold", "wind-swelling", "Han" was used for the treatment of "Water", such as wet beriberi, dysuria. Addtionally, the study of Hu indicated that *C. trilobus* was used for the treatment of "Wind", *A. heterophyla*, *A. fangchi* and *S. tetrandra* were used for the treatment of "Water" (Hu [@CR82]). Meanwhlie, crude preparations or extracts of *S. tetrandra* exhibit numerous therapeutic effects. Such crude preparations have been in recent use to safely treat arthritis (Tankeu et al. [@CR227]; Jiangsu New Medical College [@CR100]; Sekiya et al. [@CR201]), hypertension (Jiangsu New Medical College [@CR100]), apoplexy (Jiangsu New Medical College [@CR100]), edema (Jiangsu New Medical College [@CR100]), neuralgia (Kang et al. [@CR102]) and hepatic fibrosis (Sun et al. [@CR221]).

An additional important traditional use of *S. tetrandra* is in Chinese herbal formulations which consisting of two or more Chinese herbs. Han-Dan-Gan-Le is a Chinese medicinal preparation which comprising *Salvia miltorrhiza*, Radix *paeoniae*, *Astragalus membranaceus*, *S. tetrandra* and the dried leaves of *Ginkgo biloba*. Han-Dan-Gan-Le (0.5 and 1.0 g/kg, administered orally) has been used for many years to successfully treat fibrosis and cirrhosis of the liver (Li et al. [@CR125]). The decoction of Fang-Ji-Di-Huang (administered orally) which comprising *Rehmannia glutinosa* (Gaetn.) Libosch. (30 g), *S. tetrandra* (10 g), *Cinnamomum cassia* Presl (10 g), *Saposhnikovia divaricata* (Turcz.) schischk (10 g) and *Glycyrrhizae* radix et rhizome (10 g), utilized in the treatment of rheumatic arthritis (Zhao [@CR312]). Fang-Ji-Huang-Qi-Tang contains six medicinal herbs, including *S. tetrandra*, Radix *astragali*, Rhizoma *atractylodis macrocephalae*, Radix *glycyrrhizae*, Rhizoma *zingiberis* and Fructus *ziziphi jujubae*. Its extracts (25, 50 or 100 mg/kg, administered orally) is a common Chinese prescription for the treatment of painful and inflammatory disorders such as rheumatoid arthritis (Lin et al. [@CR144]) and renal edema (Gao [@CR61]). Fang-Ji-Fu-Ling-Tang comprises five herbs, including *S. tetrandra* (20 g), *Poria cocos* (Schw.) wolf (10 g), Radix *astragali* (10 g), *Cinnamomum cassia* Presl (10 g) and *Glycyrrhizae* radix et rhizome (6 g). Its extracts (administered orally) has been used in the management of post-thrombotic syndrome (Li et al. [@CR138]) and chronic heart failure (Wang and Lu [@CR242]).

Phytochemistry of *S. tetrandra* {#Sec5}
================================

The majority of studies of the phytochemistry of *S. tetrandra* have been published within the last 30 years. The vast majority have reported that the major components of *S. tetrandra* are alkaloids, almost all identified within the roots. There appear to be only five non-alkaloid constituents isolated from the aerial part of *S. tetrandra*, two bisflavones (Si and Zhao [@CR212]; Si et al. [@CR214]), *β*-sitosterol (Si and Zhao [@CR212]), stigmasterol (Liu et al. [@CR153]) and n-pentatriaeontane (Si and Zhao [@CR212]). There have been no phytochemical studies that have reported on the flowers and fruits of *S. tetrandra.* To date, a total of 67 alkaloids and 5 non-alkaloids have been identified in *S. tetrandra* (Table [1](#Tab1){ref-type="table"}). Alkaloids classified into six structural classes, including monobenzyltetrahydroisoquinolines, bisbenzyltetrahydroisoquinolines, aporphines, protoberberines and tetrahydroprotoberberines.Table 1Phytochemical content in *Stephania tetrandra* from the root and the aerial partNo.CompoundsPlant part^a^References*Monobenzyltetrahydroisoquinoline alkaloids***1***N*-methylcoclaurineRXiao et al. ([@CR265])**2**JuziphineRXiao et al. ([@CR265])**3**CoclaurineRXiao et al. ([@CR265]) and Sim et al. ([@CR216])**4**ProtosinomenineRXiao et al. ([@CR265])**5**ReticulineRXiao et al. ([@CR265])**6**Coclaurine-7-*O*-*β*-[d]{.smallcaps}-glucopyranosideRSim et al. ([@CR216])**7**OblongineRSim et al. ([@CR216])**8**Oblongine chlorideRWino et al. ([@CR258])*Bisbenzyltetrahydroisoquinoline alkaloids***9**TerandrineR and ASim et al. ([@CR215], [@CR216]), Wino et al. ([@CR258]), Tsutsumi et al. ([@CR235]), Ogino et al. ([@CR181]), Li et al. ([@CR128], [@CR129]), Si et al. ([@CR213]), Si and Zhao ([@CR211]), Deng et al. ([@CR47])**10**FangchinolineRSim et al. ([@CR215], [@CR216]), Wino et al. ([@CR258]), Tsutsumi et al. ([@CR235]), Ogino et al. ([@CR181]), Li et al. ([@CR128], [@CR129]), Deng et al. ([@CR47])**11**2′-*N*-ChloromethylterandrineRLi et al. ([@CR128], [@CR129])**12**Oxo-fangchirineRLi et al. ([@CR128], [@CR129])**13**Fenfangjine D chlorideRLi et al. ([@CR128], [@CR129])**14**( +)-2-*N*-methylfangchinolineRDeng et al. ([@CR47])**15**Terandrine 2′-*N*-*β*-oxideRWino et al. ([@CR258]), Tsutsumi et al. ([@CR235])**16**Terandrine 2′-*N*-*α*-oxideRWino et al. ([@CR258]), Tsutsumi et al. ([@CR235])**17**Terandrine 2-*N*-*β*-oxideRWino et al. ([@CR258]), Tsutsumi et al. ([@CR235])**18**Fangchinoline 2′-*N*-*α*-oxideRTsutsumi et al. ([@CR235])**19**2′-*N*-norfangchinolineRTsutsumi et al. ([@CR235])**20**CycleanorineRTsutsumi et al. ([@CR235])**21**CycleanineRWino et al. ([@CR258]), Tsutsumi et al. ([@CR235])**22**2-*N*-methylterandrineRSim et al. ([@CR215], [@CR216]), Wino et al. ([@CR258]), Tsutsumi et al. ([@CR235]), Ogino et al. ([@CR181]), Li et al. ([@CR128], [@CR129]), Si et al. ([@CR213]), Si and Zhao ([@CR211]), Deng et al. ([@CR47])**23**HomoaromalineRXiao et al. ([@CR265])**24**StephibaberineRXiao et al. ([@CR265])**25**CepharanthineRXiao et al. ([@CR265]), Sim et al. ([@CR216])**26**ObaberineRXiao et al. ([@CR265])**27**IsotetrandrineRXiao et al. ([@CR265])**28**NorthalrugosdineRXiao et al. ([@CR265])**29**2-NorcepharanthineRSim et al. ([@CR216])**30**2-*N*-methyltetrandrinium chlorideRWino et al. ([@CR258])**31**2′-*N*-methyltetrandrinium chlorideRWino et al. ([@CR258]), Tsutsumi et al. ([@CR235])**32**2,2′-*N,N*-dimethyltetrandrinium dichlorideRWino et al. ([@CR258])**33**Fenfangjine ARWino et al. ([@CR258]), Ogino et al. ([@CR181])**34**Fenfangjine BRWino et al. ([@CR258]), Tsutsumi et al. ([@CR235]), Ogino et al. ([@CR181])**35**Fenfangjine CRWino et al. ([@CR258]), Ogino et al. ([@CR181])**36**Fenfangjine DRWino et al. ([@CR258]), Ogino et al. ([@CR181])**37**Fenfangjine HROgino et al. ([@CR181])**38**Fenfangjine IROgino et al. ([@CR181])*Aporphine alkaloids***39**DicentrineRLi et al. ([@CR128], [@CR129])**40**TazopsineRLi et al. ([@CR128], [@CR129])**41**StephadioneASi et al. ([@CR213]), Si and Zhao ([@CR211])**42**OxonantenineASi et al. ([@CR213]), Si and Zhao ([@CR211])**43**CassameridineR and ASi et al. ([@CR213]), Si and Zhao ([@CR211]), Deng et al. ([@CR47])**44**NantenineASi et al. ([@CR213]), Si and Zhao ([@CR211])**45**CassythicineASi et al. ([@CR213])**46**CorydioneASi et al. ([@CR213]), Si and Zhao ([@CR211])**47**IsoboldineRXiao et al. ([@CR265])**48**CorytuberineRXiao et al. ([@CR265])**49**MagnoflorineRXiao et al. ([@CR265]), Sim et al. ([@CR215], [@CR216])**50**DehydrocrebanineRXiao et al. ([@CR265])**51**DehydrodicentrineRXiao et al. ([@CR265])**52**RoemerineRXiao et al. ([@CR265])**53**Fenfangjine GRTsutsumi et al. ([@CR235])*Protoberberine alkaloids***54**StepharanineRXiao et al. ([@CR265])**55**DehydrodiscretamineRXiao et al. ([@CR265])*Tetrahydroprotoberberine alkaloids***56**Cyclanoline chlorideRWino et al. ([@CR258]), Tsutsumi et al. ([@CR235])**57**StepholidineRXiao et al. ([@CR265])**58**DiscretamineRXiao et al. ([@CR265])**59**IsoscoulerineRXiao et al. ([@CR265])**60**CorydalmineRXiao et al. ([@CR265])**61**TetrahydrojatrorrhizineRXiao et al. ([@CR265])**62**TetrahydropalmatineRXiao et al. ([@CR265])**63**CapaurineRXiao et al. ([@CR265])**64**CyclanolineRSim et al. ([@CR216])*Others***65**StephenanthrineRWino et al. ([@CR258]), Tsutsumi et al. ([@CR235]), Ogino et al. ([@CR181])**66**ArgentinineRWino et al. ([@CR258])**67**Fenfangjine FROgino et al. ([@CR181])Non-alkaloids**68**Stephaflavone AASi and Zhao ([@CR212]), Si et al. ([@CR214])**69**Stephaflavone BASi and Zhao ([@CR212]), Si et al. ([@CR214])**70***β*-sitosterolASi and Zhao ([@CR212])**71**StigmasterolALiu et al. ([@CR153], [@CR154], [@CR155])**72**N-pentatriaeontaneASi and Zhao ([@CR212])^a^R = root, A = the aerial part

Monobenzyltetrahydroisoquinolines {#Sec6}
---------------------------------

Eight monobenzyltetrahydroisoquinolines have been reported to be present in *S. tetrandra* (Fig. [2](#Fig2){ref-type="fig"}): (**1**) *N*-methylcoclaurine (Xiao et al. [@CR265]); (**2**) juziphine (Xiao et al. [@CR265]); (**3**) coclaurine (Xiao et al. [@CR265]; Sim et al. [@CR216]); (**4**) protosinomenine (Xiao et al. [@CR265]); (**5**) reticuline (Xiao et al. [@CR265]); (**6**) coclaurine-7-*O*-*β*-[d]{.smallcaps}-glucopyranoside (Sim et al. [@CR216]); (**7**) oblongine (Sim et al. [@CR216]) and (**8**) oblongine chloride (Wino et al. [@CR258]). Of these, *N*-methylcoclaurine, juziphine, coclaurine, protosinomenine, reticuline, coclaurine-7-*O*-*β*-[d]{.smallcaps} -glucopyranoside and oblongine have been tentatively identified using liquid chromatography-mass spectrometry (LC--MS) (Xiao et al. [@CR265]; Sim et al. [@CR216]).Fig. 2Structures of 8 monobenzyltetrahydroisoquinolines

Bisbenzyltetrahydroisoquinolines {#Sec7}
--------------------------------

Bisbenzyltetrahydroisoquinolines are the major active constituents in *S. tetrandra*. To date, 30 bisbenzyltetrahydroisoquinolines have been identified as constituents (Xiao et al. [@CR265]; Sim et al. [@CR215], [@CR216]; Wino et al. [@CR258]; Tsutsumi et al. [@CR235]; Ogino et al. [@CR181]; Li et al. [@CR128]; Si et al. [@CR213]; Si and Zhao [@CR211]; Deng et al. [@CR47]; Tian [@CR230]) (Fig. [3](#Fig3){ref-type="fig"}). Of these, homoaromaline (**23**), stephibaberine (**24**), obaberine (**26**), isotetrandrine (**27**), northalrugosdine (**28**) and 2-norcepharanthine (**29**) are the only compounds identified using LC--MS (Xiao et al. [@CR265]). The 2 and/or 2′ *N*-position of bisbenzyltetrahydroisoquinolines in *S. tetrandra* is commonly oxidized or salified with a chloride ion (Wino et al. [@CR258]; Tsutsumi et al. [@CR235]; Ogino et al. [@CR181]), as can be seen in compounds **11**, **13**, **15**, **16**, **17**, **18**, **30**, **31**, **32**, **33**, **34** and **35**.Fig. 3Structures of 30 bisbenzyltetrahydroisoquinolines

Aporphines {#Sec8}
----------

Fifteen aporphines have been reported to be present in *S. tetrandra* (Fig. [4](#Fig4){ref-type="fig"}). Only isoboldine (**47**), corytuberine (**48**), magnoflorine (**49**), dehydrocrebanine (**50**), dehydrodicentrine (**51**) and roemerine (**52**) have been tentatively identified using LC--MS (Xiao et al. [@CR265]; Sim et al. [@CR215], [@CR216]). The remaining 9 aporphines have been characterized using comprehensive spectroscopic techniques (Li et al. [@CR128]; Si et al. [@CR213]; Si and Zhao [@CR211]; Deng et al. [@CR47]).Fig. 4Structures of 15 aporphines

Protoberberines {#Sec9}
---------------

Two protoberberines, stepharanine (**54**) and dehydrodiscretamine (**55**) (Fig. [5](#Fig5){ref-type="fig"}), have been identified in *S. tetrandra* using LC--MS (Xiao et al. [@CR265]).Fig. 5Structures of 2 protoberberines

Tetrahydroprotoberberines {#Sec10}
-------------------------

In total, nine tetrahydroprotoberberines have been identified in *S. tetrandra* (Fig. [6](#Fig6){ref-type="fig"}). Only cyclanoline chloride (**56**) has been isolated from *S. tetrandra* following the application of comprehensive spectroscopic techniques (Wino et al. [@CR258]; Tsutsumi et al. [@CR235]). The others have been tentatively identified using LC--MS (Xiao et al. [@CR265]).Fig. 6Structures of 9 tetrahydroprotoberberines

Other alkaloids {#Sec11}
---------------

Three aporphine alkaloids (Fig. [7](#Fig7){ref-type="fig"}), in which C~6~--C~6a~ has been cleaved, have been isolated from *S. tetrandra* (Wino et al. [@CR258]; Tsutsumi et al. [@CR235]; Ogino et al. [@CR181]).Fig. 7Structures of 3 aporphine alkaloids with C~6~--C~6a~ cleavage

Non-alkaloids {#Sec12}
-------------

Only five non-alkaloid constituents in *S. tetrandra* were reported in literature (Fig. [8](#Fig8){ref-type="fig"}). The five non-alkaloid constituents all isolated from the aerial part of *S. tetrandra*, stephaflavone A (**68**) (Si and Zhao [@CR212]; Si et al. [@CR214]), Stephaflavone B (**69**) (Si and Zhao [@CR212]; Si et al. [@CR214]), *β*-sitosterol (**70**) (Si and Zhao [@CR212]), stigmasterol (**71**) (Liu et al. [@CR153]) and n-pentatriaeontane (**72**) (Si and Zhao [@CR212]).Fig. 8Structures of 5 non-alkaloid constituents

Pharmacological properties {#Sec13}
==========================

*S. tetrandra* has a wide range of pharmacological properties. To date, the published literature has focused principally on the alkaloids and extracts of *S. tetrandra*. The molecules that have received the greatest in-depth study of their pharmacological activity are tetrandrine (Yang et al. [@CR275]; Bhagya and Chandrashekar [@CR14]; Wang et al. [@CR253]; Xing et al. [@CR268]; Cai et al. [@CR18]), fangchinoline (Desgrouas et al. [@CR49]; Wang et al. [@CR253]; Xing et al. [@CR268]) and cepharanthine (Bailly [@CR10]; Wang et al. [@CR253]). Not only are these compounds found in *S. tetrandra*, but also in other plants known to have medicinal properties (Table [2](#Tab2){ref-type="table"}).Table 2Summary of the pharmacological properties of alkaloids isolated from *Stephania tetrandra*Pharmacological activitiesCompoundsReferencesAntimicrobial effectsAntiparasitic effects**5**,**9**, **10**, **21**, **25**, **28**, **29**, **52**Ye and Dyke ([@CR279]), Ye et al. ([@CR280], [@CR281]), Chen et al. ([@CR24], [@CR25]), Chea et al. ([@CR21]), Baghdikian et al. ([@CR6]), Fadaeinasab et al. ([@CR56]), Naman et al. ([@CR178])Antibacterial effects**9**, **52**Lee et al. ([@CR119], [@CR120]), Avci et al. ([@CR4]), Yin et al. ([@CR282])Antifungal effects**9**, **49**, **52**Li and Zhang ([@CR124]), Lv et al. ([@CR161]), Shi et al. ([@CR208]), Zhang et al. ([@CR302]), Kim et al. ([@CR108]), Ma et al. ([@CR165])Antiviral effects**3**, **10**, **21**Wan et al. ([@CR240]), Kashiwada et al. ([@CR104]), Otshudi et al. ([@CR184])Anti-inflammatory effects**1**, **5**, **9**, **10**, **21**, **25**, **39**, **49**Guo et al. ([@CR69], [@CR71]), Wang et al. ([@CR250], [@CR251], [@CR252]), Shen et al. ([@CR207]), Choi et al. ([@CR43]), Kang et al. ([@CR103]), Wu and Ng ([@CR260]), Xu et al. ([@CR269], [@CR270]), Wu et al. ([@CR264]), Nakamura et al. ([@CR177]), Yang et al. ([@CR275], [@CR276]), Kondo et al. ([@CR110]), Aota et al. ([@CR3]), Yodkeeree et al. ([@CR283]), Haque et al. ([@CR75])Anticancer/antiproliferative effects**1**, **9**, **10**, **21**, **25**, **39**, **50**, **52**Bhagya and Chandrashekar ([@CR15]), Zhang et al. ([@CR311]), Yu and Ho ([@CR285]), Tian et al. ([@CR233]), Lu et al. ([@CR158]), Lien et al. ([@CR142]), Huang et al. ([@CR89]), Meng et al. ([@CR172]), Zhu et al. ([@CR321]), Zhang et al. ([@CR306], [@CR307]), Lan et al. ([@CR118]), Bai et al. ([@CR9]), Qin et al. ([@CR190]), Wang et al. ([@CR246]), Guo and pei ([@CR68]), Singh et al. ([@CR217]), Liu et al. ([@CR153], [@CR154], [@CR155]), Lin et al. ([@CR145]), Zhang et al. ([@CR308], [@CR309], [@CR310], [@CR311]), Jiang et al. ([@CR98]), Chow et al. ([@CR45]), Cho et al. ([@CR41]), Chen et al. ([@CR31], [@CR33], [@CR34]), Wang et al. ([@CR248], [@CR249], [@CR253], [@CR254], [@CR255]), Li et al. ([@CR131], [@CR132], [@CR133], [@CR134]), Fan et al. ([@CR57]), Luo et al. ([@CR160]), Chen et al. ([@CR33], [@CR34]), Lee et al. ([@CR121]), Wang et al. ([@CR245]), Li et al. ([@CR136], [@CR137]), Guo et al. ([@CR70]), Shi et al. ([@CR210]), Wang et al. ([@CR247]), Hua et al. ([@CR85]), Gao et al. ([@CR63]), Payon et al. ([@CR186]), Rattanawong et al. ([@CR192]), Zhu et al. ([@CR322]), Wu et al. ([@CR261]), Tzeng et al. ([@CR236]), Uche et al. ([@CR237]), Konkimalla and Efferth ([@CR112]), Huang et al. ([@CR86]), Makarasen et al. ([@CR168]), Ma et al. ([@CR167])Central nervous system activityNeuroprotective effects**1**, **9**, **10**, **39**, **51**, **52**, **55**, **58**, **65**Lv et al. ([@CR163]), Ruan et al. ([@CR197]), Chiou et al. ([@CR39]), Bao et al. ([@CR12]), Li et al. ([@CR131], [@CR132], [@CR133], [@CR134]), Han et al. ([@CR72]), Zhang et al. ([@CR298]), He et al. ([@CR76]), Koh et al. ([@CR109]), Lin et al. ([@CR143]), Kim et al. ([@CR107]), Hošt\'álková et al. ([@CR79]), Kongkiatpaiboon et al. ([@CR111]), Dong et al. ([@CR54]), Ingkaninan et al. ([@CR96]), Hao et al. ([@CR74], 131--147)Sleep enhancing and hypnotic effects**9**Huang et al. ([@CR91]), Zhang et al. ([@CR304]), Zhao et al. ([@CR314])Antinociceptive effects**9**, **10**, **39**Zhao et al. ([@CR315]), Zhang and Fang ([@CR297]), Fang et al. ([@CR59]), Montrucchio et al. ([@CR174])Other central effects**9**, **44**, **49**, **58**Chen et al. ([@CR32]), Ma et al. ([@CR166]), Chen et al. ([@CR30]), Ma et al. ([@CR166]), Indra et al. ([@CR95]), Kukula-Koch et al. ([@CR113]), Manuszak et al. ([@CR169]), Meade et al. ([@CR171]), Hicks et al. ([@CR78])Cardiovascular activityAntihypertensive effects**9**, **39**Yu et al. ([@CR291]), Huang et al. ([@CR91]), Zhang et al. ([@CR304]), Wang et al. ([@CR250], [@CR251], [@CR252]), Huang et al. ([@CR88]), Teng et al. ([@CR228]), Yu et al. ([@CR286], [@CR287])Cardiovascular effects**9**, **39**, **44**, **66**Yu et al. ([@CR290]), Wong et al. ([@CR259]), Rao ([@CR191]), Huang et al. ([@CR87]), Li et al. ([@CR126], [@CR127]), Zhou et al. ([@CR317]), Pinelli et al. ([@CR187]), Shen et al. ([@CR206]), Young et al. ([@CR284]), Orallo ([@CR183]), Yu et al. ([@CR288]), Ribeiro and Leite ([@CR195]), Estellés et al. ([@CR55])Immunomodulatory effects**9**, **10**, **27**Semwal et al. ([@CR202]), Lai ([@CR115]), Sekiya et al. ([@CR201]), Seow et al. ([@CR203]), Lai et al. ([@CR116]), Yun et al. ([@CR294]), Yuan et al. ([@CR293]), Lv et al. ([@CR162]), Shan et al. ([@CR205]), Hu et al. ([@CR84]), Zhang et al. ([@CR308], [@CR309], [@CR310], [@CR311]), Zhang ([@CR296]), Sun et al. ([@CR223])Antifibrotic effectsAntifibrotic effects in pulmonary disease**9**Idec-Sadkowska et al. ([@CR94]), Liu et al. ([@CR149]), Xv and Zhou ([@CR273]), Chen et al. ([@CR35])Antifibrotic effects in liver disease**9**Li et al. ([@CR135]), Hsu et al. ([@CR81]), Park et al. ([@CR185])Other antifibrosis effects**9**Teng et al. ([@CR229]), Ning et al. ([@CR179]), Li et al. ([@CR130]), Bai and Dong ([@CR7])Antidiabetic effects**9**, **10**, **15**, **16**, **17**, **18**, **19**, **25**Tsutsumi et al. ([@CR235]), Shan et al. ([@CR204]), Hsu et al. ([@CR80]), Chen et al. ([@CR26]), Ma et al. ([@CR164]), Tsutsumi et al. ([@CR235]), Jiang et al. ([@CR98]), Samra et al. ([@CR199])Antiplatelet effects**1**, **3**, **9**, **10**, **39**Kim et al. ([@CR106]), Chen et al. ([@CR22]), Yu et al. ([@CR286], [@CR287])Miscellaneous uses**3**, **5**, **9**, **25**, **27**, **39**, **44**, **49**Wu et al. ([@CR263]), Yu et al. ([@CR292]), Jang ([@CR97]), Takahashi et al. ([@CR224]), Chen et al. ([@CR27], [@CR28], [@CR29]), Zhang et al. ([@CR300], [@CR301]), Chen et al. ([@CR23]), Martin et al. ([@CR170]), Lin et al. ([@CR146]), Zhou et al. ([@CR319]), Wang et al. ([@CR250], [@CR251], [@CR252]), Yu et al. ([@CR289]), Legendre et al. ([@CR122]), Cai et al. ([@CR19]), Hung et al. ([@CR92], [@CR93]), Hung et al. ([@CR92], [@CR93])

Antimicrobial effects {#Sec14}
---------------------

Tetrandrine represents an active bisbenyltetrahydroisoquinoline alkaloid found in *S. tetrandra* that displays direct and synergistic antimicrobial effects against bacteria, parasites, viruses and fungi.

Antiparasitic effects {#Sec15}
---------------------

To date, research of the antiparasitic effects of compounds in *S. tetrandra* has focused on their antiplasmodial activity. Furthermore, a number of in vivo studies and numerous in vitro reports have indicated that compounds in *S. tetrandra*, mostly compounds **5**, **9**, **10**, **21**, **25**, **28**, **29** and **52**, display antiparasitic effects.

In vitro studies have demonstrated that cepharanthine (**25**) (50% inhibitory concentration (IC~50~) 1.2 μM), and roemerine (**52**) (IC~50~ 17.9 μM) exhibit significant antiplasmodial activity with IC~50~ values that are relatively low and similar strong activity with control compound (Chloroquine, IC~50~ 0.7 μM) (Baghdikian et al. [@CR6]). But cepharanthine and roemerine also displayed the stronger cytotoxicity against K562S cells at IC~50~ of 3.3 μM and 16.1 μM, respectively, compared with control compound (Chloroquine, IC~50~ 32 μM) (Baghdikian et al. [@CR6]). Although reticuline (**5**) and cycleanine (**21**) showed no stronger activity than chloroquine (IC~50~ 0.002 ± 0.09 μM), reticuline and cycleanine could significantly inhibit the growth of *Plasmodium falciparum* at IC~50~ 1.18 ± 0.08 μM and 0.08 ± 0.06 μM, respectively (Fadaeinasab et al. [@CR56]). Additionally, reticuline (IC~50~ 148.0 ± 1.2 μM) and cycleanine (52.96 μg/ml) also showed weak activity against *Leishmania infantum*in vitro (García Díaz et al. [@CR64]; González-Coloma et al. [@CR67]). Nevertheless, these investigations were conducted without the use of positive control and also lack analysis of its mechanism. At the concentration of 1 × 10^−5^ μM, tetrandrine (**9**) has potent antimalarial effect on both chloroquine sensitive and resistant strains of *Plasmodum falciparum*in vitro (Ye et al. [@CR280]; Ye and Dyke [@CR279]). In vitro, fangchinoline (**10**) and cepharanthine (**25**) showed similar antiplasmodial activity (IC~50~ 0.2 μM for cepharanthine, 0.3 μM for fangchinoline), but stronger antiplasmodial activity than the control chloroquine (IC~50~ 0.6 μM) (Chea et al. [@CR21]). Also in this study, fangchinoline and cepharanthine displayed stronger cytotoxicity than chloroquine to human THP1 cells (Chea et al. [@CR21]). 2-Norcepharanthine (**29**) and cycleanine have strong antiplasmodial activities against *P. falciparum* D6 at similar IC~50~ about 80 nM compared with chloroquine (IC~50~ 6.18 ± 0.71 nM) (Angerhofer et al. [@CR2]). The result of cycleanine in this study was consistent with that of Fadaeinasab's study (Fadaeinasab et al. [@CR56]). Yet the cytotoxicity of 2-norcepharanthine and cycleanine need to be assessed. Northalrugosidine (**28**) showed the most potent in vitro activity against *Leishmania donovani* promastigotes (0.28 μM), and the highest selectivity (29.3-fold) versus its general cytotoxicity against HT-29 human colon adenocarcinoma cells (Naman et al. [@CR178]). Meanwhile the reduction in parasite burden to the murine spleen and liver after the in vivo testing of northalrugosidine at 2.8, 5.6, and 11.1 mg/kg per animal when administered intravenously supported the idea that it could be further investigated as a potential new drug candidate or lead molecule for drug discovery (Naman et al. [@CR178]). However, most of these studies lacked evaluation of compounds in vivo, and investigation of mechanism of action.

In addition to in vitro studies, tetrandrine (15 mg/kg, 30 mg/kg or 60 mg/kg) has been found to be three times more effective against chloroquine-resistant strains of *P. falciparum* than against the sensitive strain in Aotus monkeys, having even greater activity when combined with chloroquine or artemisinin (Ye et al. [@CR281]). Moreover, tetrandrine (20 mg/kg) exhibited an effect greater than albendazole against *Echinococcus multilocularis* and combining the two compounds (20 mg/kg tetrandrine and 50 mg/kg albendazole) resulted in a synergistic effect (Chen et al. [@CR24], [@CR25]). Whereas the mechanism by which this bioactivity occurs should be further investigated. The combination of cepharanthine (21 mg/kg or 63 mg /kg) with chloroquine (30 mg/kg) or amodiaquine (10 mg/kg) was demonstrated to significantly improve the survival of mice and delay parasitic recrudescence (Desgrouas et al. [@CR50]). The mechanism by which cepharanline acts against plasmodia is to block the development of *P. falciparum* in the ring stage via down-regulation of Maurer's clefts (Desgrouas et al. [@CR51]). Notwithstanding, further research models are critically required to confirm this mechanism both in in vivo models and in humans.

Antibacterial effects {#Sec16}
---------------------

Only two compounds, **9** and **52**, have been evaluated for their antibacterial effects. Tetrandrine (**9**) (200.9, 401.9 or 803.8 μM) exhibited a synergistic effect against methicillin-resistant *Staphylococcus aureus* (MRSA) when combined with the multi-drug resistant (MDR)-efflux pump substrate ethidium bromide, causing a two to fourfold reduction in the minimum inhibitory concentration (MIC) of ethidium bromide against MRSA using a combined test (Lee et al. [@CR119]). Tetrandrine at concentrations of 200.9--803.8 μM inhibited both methicillin-susceptible and methicillin-resistant strains of *Staphylococcus aureus* (*S. aureus)*, with a MIC of 401.9 μM (Lee et al. [@CR120]). Meanwhile, it was demonstrated that tetrandrine-induced damage of bacterial cell walls, in combination with potential interference of cell wall biosynthesis via its direct binding to peptidoglycan, may underlie the synergy against *S. aureus* (Lee et al. [@CR120]; Zhao et al. [@CR313]). Though the compound exhibited potent inhibitory activity against *S. aureus*, the required dose of the two compounds was excessive in these studies, the experimental data not being relevant to clinical applications. Moreover, the two studies lacked appropriate positive controls. Tetrandrine (48.23 μM), an efflux pump inhibitor as verapamil, could reverse drug resistance in 82% of isoniazid and ethambutol-dual resistant clinical isolates of *Mycobacterium tuberculosis*, but did not show a direct antibacterial activity against *Mycobacterium tuberculosis* (Zhang et al. [@CR305]). Quite on the contrary, another study revealed that tetrandrine at 12.86--51.44 μM exerted strong direct tuberculostatic activity against 16 *Mycobacterium tuberculosis* strains in vitro (Vichkanova et al. [@CR239]). Yet these investigations were conducted without the use of positive control, and the direct antibacterial activity against *Mycobacterium tuberculosis* of tetrandrine need to be validated furtherly. In both in vitro and in vivo studies, roemerine (**52**) (MICs ranging from 114.7 μM to 229.4 μM in vitro; the concentration of 20 mg/kg was used in vivo) demonstrated antibacterial effects towards methicillin susceptible and methicillin-resistant strains, and increased bacterial cell membrane permeability in a concentration-dependent manner (Yin et al. [@CR282]). More importantly, roemerine (229.4 μM) showed similar antibacterial effects with positive controls of vancomycin (11.0 μM) and oxacillin (638.4 μM) in this study (Yin et al. [@CR282]). The antibacterial mechanisms of roemerine (from 268.8 to 358.4 μM) demonstrated that it accumulates intracellularly, but it is susceptible to being subject to efflux from cells through multidrug resistant transporter proteins (Avci et al. [@CR4]). Roemerine was shown to be effective against *Escherichia coli*in vitro (Ayyildiz et al. [@CR5]; Gokgoz and Akbulut [@CR66]). By assessing these studies, the concentrations of roemerine were too high to be considered antibacterial effects towards methicillin susceptible and methicillin-resistant strains (Cos et al. [@CR46]; Gertsch [@CR65]). Moreover, roemerine was not be evaluated for cytoxicity at such high concentrations in these studies. Additionally, cycleanine showed broad antibactericidal effects on *Bacillus subtilus*, *Cornynebacterium diphtheria*, *Klebsiella pneumonia*, *Pseudomonas aeruginosa*, *Salmonella typhi*, *Streptococcus pyogenes* at the concenrtaion of 1607.7 μM (Lohombo-Ekomba et al. [@CR156]). As the same above problem, it is still somewhat doubtful whether the broad antibactericidal effects of cycleanine found at such high concentration are meaningful. Moreover, this study had other shortages, including no evalution of solvent activity and a single dose of cycleanine, resulting into lower reliability and absence of dose-dependent effect.

Antifungal effects {#Sec17}
------------------

To date, the antifungal effects of *S. tetrandra* have principally focused on *Candida albicans*. Tetrandrine (**9**) (48.2--64.3 μM) exhibits synergistic effects with fluconazole against both fluconazole-sensitive and fluconazole-resistant *Candida albicans* (*C. albicans*) (Li and Zhang [@CR124]; Lv et al. [@CR161]; Zhao et al. [@CR316]; Benhamou et al. [@CR13]; Zhang et al. [@CR300], [@CR303]) and also directly inhibits *C. albicans* in mice (Shi et al. [@CR208]). Nonetheless, these studies lacked appropriate positive controls and adequately broad dose range. Moreover, the synergistic effects of tetrandrine should be doubted at such high concentrations (Cos et al. [@CR46]; Gertsch [@CR65]). In a mouse candida vaginitis model, vaginal administration of 13 mg/kg/day of tetrandrine also had a synergistic antifungal effect when combined with ketoconazole against *C. albicans* (Zhang et al. [@CR302]). But, only a single dose of tetrandrine was used throughout the study, limiting the reliability of the dose--response characterisitics. Moreover, this investigation was conducted without the use of a positive control. In addition, tetrandrine (20, 40 or 60 mg/kg/day) exhibits synergistic effects with posaconazole or itraconazole or voriconazole against *Aspergillus fumigatus*in vitro and in vivo, and the synergistic mechanism was related to inhibition of the drug efflux pump (Li et al. [@CR131], [@CR136]). Magnoflorine (**49**) has demonstrated a substantial ability to inhibit the growth of *Candida* strains, as evidenced by a reduction in formation of a *C. albicans* biofilm at a MIC of 106.6 μM, based on microdilution antifungal susceptibility testing. Magnoflorine didn't have any toxicity to HaCaT cells even in 600 μM of treatment (Kim et al. [@CR108]). The main limitations of the study are that high doses of magnoflorine were used and the study lacked a positive control. Compared with positive control amphotericin B (0.04 µg/disc), *α* or *β*-magnoflorine (5.0 µg/disc or 10 µg/disc) showed weak antifungal activities against *Penicillium avellaneum* UC-4376 (Chen et al. [@CR27]). Furthermore, only a single dose of *α* or *β*-magnoflorine were used throughout the studies, and thus limited the information on the dose-dependent effect. Roemerine (**52**) at 3.58 µM was also shown to inhibit the formation of a *C. albicans* biofilm in vitro, possibly related to the cyclic adenosine monophosphate (cAMP) pathway (Ma et al. [@CR165]). The toxicity of roemerine was investigated in this study that roemerine had no significant toxicity using *Candida elegans* worms, three cancer cells and one normal cell (Ma et al. [@CR165]). However, roemerine in this study was not observed to have a fungicidal effect against planktonic *C. albicans* cells. Another experiment showed that roemerine had antifungal activities against *C. albicans*in vitro at IC~50~ 16.1 µM and MIC 35.84 µM, and no cytotoxic effects towards mammalian kidney fibroblasts (the kidney cells of the African green monkey) up to a concentration of 85.3 μM (Agnihotri et al. [@CR1]). Nonetheless, this investigation was conducted without the use of positive control. Cycleanine at the concentraion of 3215.4 μM showed broad antifungicidal effects on *Trichophyton longiformis*, *Candida albicans*, *Aspergillus flavis*, *Microsperum canis*, *Fusanum solani var lycopersici-tomato*, *Emoniliform spp*. when ketoconazole or amphotericin B flucytosine or benlate nabam being the control (Lohombo-Ekomba et al. [@CR156]). At such high concentration, the result of broad antifungicidal effects of cycleanine is unreliable, and also cytotoxicity assay was not investigated in this study.

Antiviral effects {#Sec18}
-----------------

Limited research has been published regarding the antiviral activity of the alkaloids and extracts of *S. tetrandra*. Fangchinoline (**10**) exhibited antiviral activity against HIV-1 laboratory strains NL4-3, LAI and Bal in MT-4 and PM1 cells with a 50% effective concentration ranging from 0.8 to 1.7 μM by interfering with gp160 proteolytic processing (Wan et al. [@CR240]). Nevertheless, this study lacked positive control in vitro, which further compromised the quality of the study. Compared with positive control drug (zidovudine, EC~50~ 0.045 ± 0.056 μg/ml), coclaurine (**3**) demonstrated potent anti-HIV activity with an EC~50~ value of 0.8 μg/ml, and low cytotoxicity (IC~50~ \> 100 μg/ml) (Kashiwada et al. [@CR104]). However, an experimental animal model must also be established to further verify the anti-HIV activity of coclaurine. Cycleanine (**21**) has been observed to act against HIV-2 (EC~50~ = 2.94 μM) but it was at least tenfold less active against HIV-1 (Otshudi et al. [@CR184]). Tetrandrine (**9**) (1--10 μM), dose-dependently suppressed dengue virus production in A549 cells by activating cycloxygenase-2 (COX-2) expression, and nuclear factor κB (NF-κB) and activator protein 1 (AP-1) activity (Liou et al. [@CR147]). Although tetrandrine (intraperitoneal administration of 30 mg/kg/day) potently inhibited herpes simplex virus type-1-induced keratitis in BALB/c mice by modulating murine herpes simplex keratitis (HSK) development at least partly by modifying the host immune/inflammatory response to the virus in vivo (Hu et al. [@CR83]), future studies should attempt to evaluate the toxicity of tetrandrine in vivo. In vitro, cepharanthine (0.21--26.4 μM) or its cepharanthine hydrochloride (0.01--100 μM) demonstrated potent inhibiting wild-type and lamivudine-resistant hepatitis B virus (HBV) clinical isolates, herpes simplex virus type-1 (HSV-1) and herpes simplex virus type-2 (HSV-2) (Zhou et al. [@CR318]; Liu et al. [@CR150]; Qian et al. [@CR189]). The major limitation of these studies were only conducted in vitro, and lacked further study in mechasim of action. In vitro, cepharanthine had also antiviral activity against severe acute respiratory syndrome coronavirus, with IC~50~ values of the four treatments ranged between 9.9 and 15.67 μM (Zhang et al. [@CR299]), but this study lack positive control and in vivo study. Tetrandrine, an L-type calcium channel inhibitor, has been shown to inhibit two-pore Ca^2+^ channels in the late endosome/lysosome and subsequently block Zaire ebola virus entry in vitro with an IC~50~ of 55 nM (Sakurai et al. [@CR198]; Schafer et al. [@CR200]). Tetrandrine was further evaluated in a mouse model of ebola infection and shown to significantly decrease morbidity, mortality, and viral titers (Sakurai et al. [@CR198]; Rhein and Maury [@CR194]). Still and all, the antiviral effects of *S. tetrandra* have not been studied in sufficient detail, additional research being required to assess the pharmacological and mechanistic characteristics of a greater number of its components.

Anti-inflammatory effects {#Sec19}
-------------------------

Traditionally, *S. tetrandra* has been utilized as a TCM because of its anti-inflammatory properties. For this purpose, aqueous extracts of *S. tetrandra* are most commonly used. Such aqueous extracts and alkaloids of *S. tetrandra* (0.07813, 0.15625 or 0.31250 mg/ml) have been demonstrated to mediate against inflammation induced by lipopolysaccharide (LPS) in RAW264.7 cells, through inhibition of the release of nitric oxide, tumor necrosis factor (TNF)-α and interleukin (IL)-6 (Guo et al. [@CR69]). Moreover, aqueous extracts and the alkaloids of *S. tetrandra* below the concentration of 0.31250 mg/ml did not exerted cytotoxicity to RAW264.7 cells (Guo et al. [@CR69]). Interestingly, another study showed that total alkaloids from *S. tetrandra* decotion had the similar anti-inflammatory effects, mechanism, and cytotoxicity (Wang et al. [@CR250]). *S. tetrandra* extract, tetrandrine (**9**) (1.6--16.0 μM) and fangchinoline (**10**) (1.64--16.4 μM) also exert anti-inflammatory effects by interfering with reactive oxygen species (ROS) production and Ca^2+^ influx through G protein modulation to prevent macrophage adhesion molecule-1 (Mac-1) up-regulation in activated neutrophils (Shen et al. [@CR207]). In the study, phytochemical analysis of *S. tetrandra* extracts was not conducted. Moreover, the study lack positive control, which further compromised the quality of the study. A lot of literature have reported anti-inflammatory effects of tetrandrine (concentrations of 0.1--100 μM for in vitro studies, concentrations of 6.25--80.0 mg/kg for in vivo studies) by various signalling pathways, such as nuclear factor κB (NF-κB) pathway, phosphoinositide 3-kinase (PI3K) pathway, extracellular regulated protein kinases (ERK) pathway, and signal transducers and activators of transcription 3 (STAT3) signaling pathway, etc. (Wu and Ng [@CR260]; Xu et al. [@CR269]; Wu et al. [@CR264], [@CR263]; Zhang et al. [@CR301]; Choi et al. [@CR43]; Kang et al. [@CR103]; Li et al. [@CR139]; Bao et al. [@CR12]; Gao et al. [@CR62]; Wang et al. [@CR248]; Xue et al. [@CR272]). In these in vivo studies, tetrandrine displayed equivalent or stronger anti-inflammatory effects compared with their positive control drugs, such as indomethacin, methotrexate (Wu et al. [@CR264]; Li et al. [@CR139]; Gao et al. [@CR62]). However, most of these in vitro studies lacked positive controls, and the evaluation of anti-inflammatory effects in vivo (Wu and Ng [@CR260]; Xu et al. [@CR269]; Wu et al. [@CR263]; Zhang et al. [@CR301]; Choi et al. [@CR43]; Kang et al. [@CR103]; Bao et al. [@CR12]; Wang et al. [@CR248]; Xue et al. [@CR272]). Fangchinoline (**10**) and tetrandrine (**9**) are the major alkaloids in *S. tetrandra* traditionally used to treat inflammatory diseases in Asian countries, including China, Japan and Korea. Both fangchinoline (4.0 μM) and tetrandrine (6.0 μM) have demonstrated anti-inflammatory effects towards mouse ear edema induced by croton oil, although the two compounds have been shown to act through different mechanisms. The same concentration (12.5 μM) of fanchinoline and tetrandrine have demonstrated different effects on cyclooxygenase (COX), murine interleukin-5 (IL-5) and human IL-6 (Choi et al. [@CR43]). Although fangchinoline exhibited stronger anti-inflammatory effect than tetrandrine, this study conducted without the use of a proper positive control. Tetrandrine (10--50 μM) exhibits anti-inflammatory effects through various mechanisms, including the suppression of extra-signal response kinase (ERK1/2), c-jun *N*-terminal kinase (JNK1/2), inhibition of the phosphorylation and degradation of inhibitor of kappa B (IκB) and activation of NF-κB (Kang et al. [@CR103]). Although detailed research was performed into anti-inflammatory mechanisms in this study, a major limitation was lack of a positive control.

Tetrandrine at the concentration of 10 μM or 50 μM has also been shown to suppress the expression of COX-2 and inducible nitric oxide synthase (iNOS) (Wu and Ng [@CR260]), and inhibit NF-κB and extracellular regulated protein kinase (ERK) signal transduction. It has also been shown to reduce activation of the STAT3 signaling pathway (Xu et al. [@CR269]). Furthermore, tetrandrine (administration of 40 mg/kg/day) has been shown to suppress a systemic inflammatory response and multiple organ dysfunction syndrome, thus protecting against damage (Wu et al. [@CR264]). Nevertheless, dose-dependent effects were not observed in each case and some of the investigations lacked positive controls. Tetrandrine (3.21--16.07 μM) may play an important role in the prevention of glomerulonephritis by down-regulation of ERK/NF-κB signaling and inhibition of the activation of mesangial cells (Wu et al. [@CR263]). Yet the authors of this study did not perform comparisons using a positive control. Moreover, the concentrations conducted in this study were lower than other anti-inflammatory effect studies of tetrandrine. Administration 40 mg/kg of tetrandrine not only decreased DNA binding by NF-κB but also reduced the accumulation of leukocytes, downregulated IL-1β and TNF-α production, limited the inflammatory response and thereby significantly ameliorated the severity of dextran sulfate sodium-induced colitis (Zhang et al. [@CR301]). However, the safety or side effects of tetrandrine were not addressed in this study, aspects which should be established via a toxicity study prior to use in a human study.

Anyhow we hold that tetrandrine could be a potent anti-inflammatory agent for further drug development after completing in vivo toxicity and in vivo metabolic assessment.

Reticuline (**5**) at the concentration of 0.5 mg/kg was shown to possess anti-inflammatory effects against xylene-induced ear edema and carrageenan-induced paw edema in mice and rats. The effects were mediated through inhibition of TNF-*α* and IL-6 mRNA expression, by reducing phosphorylation of Janus kinase 2 (JAK2) and STAT3 (Yang et al. [@CR276]). Nonetheless, this investigation was conducted without the use of positive control, and also lacks analysis of dose-effects relationship of reticuline. Cepharanthine (**25**), cycleanine (**21**) and tetrandrine (**9**) (each at a concentration of 5 μg/ml) significantly suppressed NO production, exerting anti-inflammatory activity (Kondo et al. [@CR110]). However, only a single dose of these compounds was used throughout these studies, thus limiting data regarding the effect being dose-dependent. Cepharanthine at concentrations of 33.0 μM and 82.5 μM were also shown to inhibit chemotaxis of Jurkat T cells by reducing chemokine (C-X-C motif) ligand 10 (CXCL10) production, resulting in suppression of inflammation (Aota et al. [@CR3]). It's worth noting that this study also did not include a positive control. Meanwhile, this study conducted higher concentration of cepharanthine than that of Kondo's study to evaluate the anti-inflammatory activity. Dicentrine (**39**) at the concentrations of 5.90, 7.52 or 10.0 μM was shown to suppress LPS-induced inflammation by blocking the activation of NF-κB and activator protein-1 (AP-1) through inhibition of mitogen-activated protein kinase (MAPK) and p-protein kinase B (Akt) signaling in RAW264.7 macrophages (Yodkeeree et al. [@CR283]). Although this study assessed the cytotoxicity to RAW264.7 macrophages, anti-inflammatory effects and the mechanism of action, these authors did not compare the efficacy of dicentrine with a positive control. Magnoflorine (**49**) (3.125--50 μM) enhanced an LPS-activated pro-inflammatory response by upregulating TNF-α, IL-1β, prostaglandin E2 (PGE2) production and COX-2 protein expression in U937 macrophages. Compared to the positive control of levamisole, magnoflorine showed weaker the 50% effective dose (ED~50~) values of 7.89 and 10.28 µM for TNF-α and IL-1β, respectively. (Haque et al. [@CR75]). In an in vivo trial, magnoflorine (5--20 mg/kg) ameliorated acute lung injury induced by LPS by suppressing the activation of NF-κB and MAPK (Guo et al. [@CR71]). However, no clinical trials have been reported and so further evidence in humans is required to assess the anti-inflammatory effect of magnoflorine.

Multiple components in *S. tetrandra* demonstrate anti-inflammatory activity through various mechanisms. These results reinforce the use of this plant as an anti-inflammatory agent, complimenting the traditional use of this plant as a treatment for inflamed sores.

Anticancer/antiproliferative effects {#Sec20}
------------------------------------

A large body of literature has reported that *S. tetrandra* and its alkaloids have anticancer and antiproliferative effects in various malignant tumor cells. In this regard, fangchinoline (**10**) and tetrandrine (**9**) remain the most studied constituents of *S. tetrandra*. Tetrandrine has broad-spectrum antitumor effects (Bhagya and Chandrashekar [@CR15]; Liu [@CR148]; Liu et al. [@CR152]) in many types of cancer cells, including human liver cancer (Zhang et al. [@CR308]; Yu and Ho [@CR285]), osteosarcoma (Tian et al. [@CR233]; Lu et al. [@CR158]), oral cancer (Lien et al. [@CR142]; Huang et al. [@CR89]), colon carcinoma (Meng et al. [@CR172]; Li et al. [@CR140]), gastric cancer (Bai et al. [@CR9]; Qin et al. [@CR190]), brain glioblastoma multiforme GBM 8401 cancer (Jiang et al. [@CR99]) and lung carcinoma (Chow et al. [@CR45]; Cho et al. [@CR41]). It also exhibits antineoplastic activity against gallbladder carcinoma (Zhu et al. [@CR321]), thyroid carcinoma B-CPAP cells (Zhang et al. [@CR306]), prostatic carcinoma PC3 cells (Lan et al. [@CR118]), esophageal cancer (Wang et al. [@CR246]), breast cancer (Guo and Pei [@CR68]), pancreatic cancer (Singh et al. [@CR217]), nasopharyngeal carcinoma (Lin et al. [@CR145], [@CR154]), acute megakaryoblastic leukemia (Liu et al. [@CR155]), cervical cancer (Zhang et al. [@CR309]) and renal carcinoma (Chen et al. [@CR31], [@CR33]) cells. Although tetrandrine exhibited broad anti-tumor effects, a number of these studies lacked positive controls or anti-tumor evaluation of tetrandrine in vivo. It is a challenge to compare each other in quantitative data on these activities as a result of different tumor models and different cell lines of the same cancer.

As a result of the structural similarity with tetrandrine (**9**), fangchinoline (**10**) also has significant antitumor activity in various types of cancers, including carcinoma of the breast (Wang et al. [@CR249], [@CR254]), prostate (Li et al. [@CR132]), bladder (Fan et al. [@CR57]), lung (Luo et al. [@CR160]), stomach (Chen et al. [@CR34]), pancreas (Lee et al. [@CR121]) and liver (Wang et al. [@CR245]). It also acts against osteosarcoma (Li et al. [@CR137]), glioblastoma (Guo et al. [@CR70]), melanoma (Shi et al. [@CR210]) and chronic myelogenous leukemia (Wang et al. [@CR256]). Still and all, additional investigation using in vivo models with appropriate positive controls, dose, and standards is required.

In addition to fangchinoline (**10**) and tetrandrine (**9**), a number of other alkaloids in *S. tetrandra* have also reported anticancer/antiproliferative effects. Cepharanthine (**25**) was shown to possess potent cytotoxicity against a number of types of carcinoma cell, including those of the lung (Hua et al. [@CR85]), breast (Gao et al. [@CR63]), ovary (Payon et al. [@CR186]), colon and rectum (Rattanawong et al. [@CR192]). It also acts against choroidal melanoma cells (Zhu et al. [@CR322]) and K562 human leukemia cells (Wu et al. [@CR261]). These anticancer effects of cepharanthine are only in vitro investigation, whereas anti-tumor evaluation of cepharanthine in vivo need to be verified. *N*-methylcoclaurine (**1**) has demonstrated potential therapeutic effects against leukemia (IC~50~ \< 10 μM) in studies evaluating its impact on the growth of murine leukemic L1210 cells, human leukemic CCRF-CEM cells and HL-60 cells (Tzeng et al. [@CR236]). Cycleanine (**21**) with the IC~50~ values from 7 to 14 μM showed potential anti-cancer effects on various ovarian cancer cells by acting through the apoptosis pathway. Yet compared to the positive control, paclitaxel (IC~50~ values from 5 to 8 nM), anti-cancer effects on various ovarian cancer cells of cycleanine has no advantage. (Uche et al. [@CR237]). Dicentrine (**39**) has been shown to IC~50~ values from 4 to 43 μM on different U87MG cell lines by inhibiting the over-expression of epidermal growth factor receptor cancer cells by intercalation of DNA and the introduction of DNA strand breaks. Unfortunately, this study did not use a positive control, which compromised the quality of the study (Konkimalla and Efferth [@CR112]). In severe combined immunodeficiency mice, dicentrine (100 μg/mice) significantly inhibited the development of tumors in the leukemia cell line K562. Alternatively, dicentrine (14.7 μM), in vitro, could decrease the colony formation efficiency in both hepatoma cell lines, HuH-7 and MS-G2. (Huang et al. [@CR86]). It is a pity that only one dose of dicentrine used in the in vivo and in vitro studies, and thus limited the information on the dose-dependent effect. And the dose of dicentrine should be used in μg/kg based on the weight of mice instead of μg/mice in the in vivo study. Dehydrocrebanine (**50**) has demonstrated strong activity against promyelocytic leukemia cells (HL-60), with an IC~50~ of 6.35 µM (Makarasen et al. [@CR168]). Though, the mechanism of action and in vivo activity need further assessment. Roemerine (**52**) was shown to anti-prostate cancer effect in vivo in the mouse model of prostate cancer, while in vitro inhibit the proliferation and migration of the following prostate cancer cell lines: DU145, LNCaP, PC-3 and 22RV1. It also induced different degrees of apoptosis, particularly in LNCaP cells (Ma et al. [@CR167]). The shortage of this study was that only a single dose of roemerine was used.

A number of mechanisms are involved in the manner in which the constituents of *S. tetrandra* act against various carcinoma cells, including induction of tumor cell apoptosis (Zhu et al. [@CR321]; Zhang et al. [@CR306]; Bai et al. [@CR9]; Liu et al. [@CR154]; Chen et al. [@CR31]; Wang et al. [@CR254]; Fan et al. [@CR57]), tumor cell autophagy (Zhang et al. [@CR309]; Lien et al. [@CR142]; Huang et al. [@CR89]; Bai et al. [@CR9]; Guo and Pei [@CR68]; Fan et al. [@CR57]; Gao et al. [@CR63]), tumor cell cycle blockade (Singh et al. [@CR217]; Chen et al. [@CR31]; Luo et al. [@CR160]; Gao et al. [@CR63]) and inhibition of tumor cell invasion and metastasis (Zhang et al. [@CR308]; Li et al. [@CR137]; Shi et al. [@CR210]). Reversal of multidrug resistance is an additional important mechanism of the anticancer effects of tetrandine (**9**) and fangchinoline (**10**). These two compounds are effective in overcoming multidrug resistance in a variety of tumor cells in a synergistic manner via modulation of P-glycoprotein (Choi et al. [@CR42]; Sun and Wink [@CR219]; Lu et al. [@CR158]), multidrug resistance-associated protein 1 (Wang et al. [@CR246]), multidrug efflux transporters (Yao et al. [@CR277]), Akt/NF-κB/matrix metalloprotein (MMP)-9 (Chen et al. [@CR33]) and β-catenin expression (Zhang et al. [@CR307]). Tetrandine has also been shown to enhance radiation sensitization for human nasopharyngeal carcinoma cells by modulating phosphorylated histone H2AX (γ-H2AX), phosphorylated CDC25C, phosphorylated cyclin-dependent kinase 1 (p-CDK1) and CDK1 (Ding et al. [@CR52]; Wang et al. [@CR255]). In lung cancer cells, tetrandine decreased the proportion of cells blocked at G2 (Ding et al. [@CR53]) and also enhanced the radiation sensitization of esophageal carcinoma cells (Bai et al. [@CR8]). To date, tetrandine is the only alkaloid of *S. tetrandra* which has been reported to enhance radiation sensitization in various cancer cells. As these studies of mechanisms were only conducted in vitro, additional researches using in vivo models with appropriate controls and doses are required.

In summary, alkaloids in *S. tetrandra* have favorable anti-tumor effects. Furthermore, some alkaloids of *S. tetrandra* has the potential to be developed into novel anti-tumor drugs because of the mechanisms already defined and its pharmacological effects.

Central nervous system activity {#Sec21}
-------------------------------

### Neuroprotective effects {#Sec22}

Tetrandrine (**9**) and fangchinoline (**10**) are protective against the neurodegeneration occurring in Alzheimer\'s and Parkinson\'s disease. Rats were injected intraperitoneally with 10 or 30 mg/kg tetrandrine every other day for 4 weeks, tetrandrine has been shown to exert neuroprotective effects in chronic vascular dementia by reducing IL-1β expression, *N*-methyl-D-aspartate receptor 2B phosphorylation at tyrosine 1472 and neuronal necrosis (Lv et al. [@CR163]). However, no positive control was included in these animal experiments and a dose--response effect was not observed. In a mouse model of middle cerebral artery occlusion (MCAO), two-dimensional difference gel electrophoresis (2-D DIGE) revealed that tetrandrine at the dose of 30 mg/kg attenuated cerebral ischemia/reperfusion injury and induced differential proteomic changes (Ruan et al. [@CR197]). Nevertheless, the experiment had a number of limitations, including having no positive control and a single dose of drugs, resulting in a lower level of reliability and no possibility of observing a dose-dependent effect. Tetrandrine at the concentrations of 0.5 and 1.0 µM has also been shown to diminish the harmful effects of amyloid-*β* protein on cell survival by interfering with signals of necrosis relating to Ca^2+^ overload through L-type calcium channels (Chiou et al. [@CR39]). Furthermore, tetrandrine (0.1--20 µM) also protects against injury induced by oxygen-glucose-serum deprivation/reoxygenation (OGSD/R) (Bao et al. [@CR12]). Tetrandrine has been shown to facilitate the neuroprotective effects of glutathione in a 6-hydroxydopamine-lesioned rat model in Parkinson\'s disease at the dose of 15 mg/kg/day (Li et al. [@CR133]), reduce phenobarbital withdrawal symptoms and protect brain cells against apoptosis at the doses from 6.25 to 31.25 mg/kg/day (Han et al. [@CR72]). Tetrandrine can also alleviate pathological nerve cell damage (Zhang et al. [@CR298]) and ameliorate Aβ (1--42)-induced spatial learning and memory deficit in Alzheimer\'s disease at the dose of 40 mg/kg/day (He et al. [@CR76]). Nonetheless, because the factors affecting nerve cell damage or Alzheimer\'s disease are numerous, the signaling pathways are extremely complex and the signaling molecules involved are in considerable abundance. Thus, the mechanism of tetrandrine in nerve cell protection and the treatment of Alzheimer\'s disease requires additional in-depth basic research including a search for factors that modulate the neuroprotective effects of tetrandrine, to explore related signaling molecules and pathways involved in the neuroprotective effects. Tetrandrine (**9**) and fangchinoline (**10**) over a concentration range of 0.1--10 µM have been shown to lessen the harmful effects of H~2~O~2~-induced neuronal cell death by interfering with increased Ca^2+^ concentrations, which inhibit glutamate release and generation of reactive oxygen species (ROS) (Koh et al. [@CR109]). Yet this investigation was conducted without the use of a positive control. Furthermore, fangchinoline inhibited glutamate release from rat cortical synaptosomes by suppressing the activity of the voltage-dependent Ca^2+^ channels, with an IC~50~ values derived from a dose--response curve of about 93 µM, subsequently causing a reduction in the ingress of Ca^2+^ into nerve terminals (Lin et al. [@CR143]; Kim et al. [@CR107]). This investigation, too, was conducted without the use of a positive control. And the IC~50~ value (93 µM) was too high, which can not provide reliable experimental data for clinical application.

Butyrylcholinesterase and acetylcholinesterase (AChE) play important roles in Alzheimer\'s disease. *N*-methylcoclaurine (**1**), reticuline (**5**), dicentrine (**39**), dehydrodicentrine (**51**), roemerine (**52**), Stepharanine (**54**) and cyclanoline (**64**) have demonstrated inhibitory effects against AChE with IC~50~ value of 15.0 ± 1.4 µM, 33.6 ± 3.0 µM, 6.6 µM, 2.98 µM, 335.1 µM, 14.10 ± 0.81 µM, and 9.23 ± 3.47 µM, respectively (Hošt\'álkováet al. [@CR79]; Kongkiatpaiboon et al. [@CR111]; Dong et al. [@CR54]; Ingkaninan et al. [@CR96]). Among them, roemerine showed the weakest acetylcholinesterase inhibitory activity. Compared with the positive control of tacrine, with IC~50~ value of 0.25 µM, the activities of these compounds are not strong. Investigations on potential mechanisms and in vivo study are required, since AChE inhibitory activity of these compounds was merely evaluated by analysis of their IC~50~ values. Stepholidine (**57**) at the doses of 3--10 mg/kg should be explored as a potential therapeutic drug for Alzheimer\'s disease because it acts through a mechanism that improves trafficking of the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor and improves synaptic plasticity by activating the dopamine D1 receptor/protein kinase A (D1/PKA) signaling pathway (Hao et al. [@CR74]). Nevertheless, this study also lacked a positive control and no analysis of dose-dependency has been conducted. These limitations put into question the reliability of this study.

### Enhancement of sleep and hypnotic effects {#Sec23}

Tetrandrine (**9**) is the sole constituent of *S. tetrandra* that has been studied for its effects on initiating sleep. Intragastric administration of tetrandrine (60 mg/kg/day) significantly decreased the c-Fos positive ratio of noradrenergic neurons in the locus coeruleus (LC) of spontaneously hypertensive rats. It also significantly decreased norepinephrine in endogenous pathways that regulate sites that modulate the sleep--wake cycle, such as the LC, hypothalamus and ventrolateral preoptic nucleus (Huang et al. [@CR91]). Yet the authors did not explore dose-dependency, because only two doses were evaluated in this study. Tetrandrine (100 mg/kg, administered orally) has also been shown to markedly improve sleep efficiency by increasing the time of total sleep, rapid eye movement (REM) sleep and non-REM sleep, including deep sleep and light sleep (Zhang et al. [@CR304]). Unfortunately, only a single dose of tetrandrine was used throughout the study, with no investigation of dose-dependency. Moreover, the dose of tetrandrine used was too high in the study, it can not provide reliable experimental data for clinical application. In mice, tetrandrine (30 or 60 mg/kg, administered orally) has also been shown to significantly potentiate pentobarbital-induced hypnosis by reducing sleep latency and increasing sleeping time in a dose-dependent manner, an effect potentiated by 5-hydroxytryptophan (Zhao et al. [@CR314]). In general, future studies should attempt to identify the mechanism of action of tetrandrine.

### Antinociceptive effects {#Sec24}

Tetrandrine (**9**) (15, 30 or 45 mg/kg, administered intraperitoneally) exhibits antinociceptive effects against LPS-induced hyperalgesia in mice. These effects mediated by inhibition of inhibitor kappa B kinaseβ (IKKβ) phosphorylation. This has been shown to reduce the production of important pain mediators, such as PGE2 and COX-2 via the IKKβ/IκB/NF-κB pathway (Zhao et al. [@CR315]). In this study, tetrandrine exhibited stronger antinociceptive effects than the positive control morphine (10 mg/kg). In the study, further research models are critically needed to confirm such activity *in-vivo* and in humans. Dicentrine (**39**) (100 mg/kg/day, administered orally) has demonstrated significant antinociceptive activity in a mouse model of acute visceral pain. It also reduced spontaneous nociception and attenuated mechanical and cold hypersensitivity, probably via a transient receptor potential ankyrin 1 (TRPA1)-dependent mechanism (Montrucchio et al. [@CR174]). This investigation, too, was conducted without use of a positive control, and also lacked analysis of a dose--response, as well as the dose of dicentrine was used too high. Though research on the antinociceptive effects of *S. tetrandra* is limited, these results compliment the traditional use of this plant in the treatment of arthralgia.

### Other central effects {#Sec25}

Reticuline (**5**) possesses potent central nervous system depressant action. In vivo, reticuline (50--100 mg/kg, administered intraperitoneally) could produce alteration of behaviour pattern, prolongation of pentobarbital-induced sleep, reduction in motor coordination and d-amphetamine-induced hypermotility and suppression of the conditioned avoidance response (Morais et al. [@CR175]). This study had the same shortage of lacking a positive control. Tetrandrine (**9**) (40 mg/kg, administered intraperitoneally) appears to be a potential adjuvant drug for the treatment of refractory epilepsy. It has demonstrated decreased cell resistance to phenytoin and valproic acid. It also reduced the frequency of seizures and increased the efficacy of antiepileptic drugs by reducing the expression of P-glycoprotein at both mRNA and protein levels in vivo (Chen et al. [@CR32]). Anyhow, safety and efficacy data should be established, especially via a toxicity study prior to evaluation in a human study. Tetrandrine (30 mg/kg, administered intraperitoneally) also ameliorated sevoflurane-induced cognitive impairment by suppression of inflammation and apoptosis in aged rats. Thus, tetrandrine may potentially be a novel candidate to protect cognitive function against the effects of sevoflurane anesthesia (Ma et al. [@CR166]). A limitation of this study was the single dose of tetrandrine used and not a positive control. Tetrandrine (10 mg/kg or 30 mg/kg, administered intraperitoneally) was also shown to reduce cognitive impairment in chronic cerebral hypo-perfused rats by inhibition of the activation of S100B and a decrease in the expression of IL-1β, TNF-α and iNOS in the hippocampal CA1 region (Chen et al. [@CR30]). The limitations of this study were the single dose of tetrandrine used and the lack of a positive control.

Nantenine (**44**) (13.3, 20 and 30 mg/kg, administered intraperitoneally) has demonstrated inhibition of the head-twitch response induced by 5-hydroxytryptophan (5-HT) plus clorgyline by blocking 5-HT 2A (5-HT2A) receptors in the central nervous system. The positive control ketanserin at the doses of 0.0625, 0.25 and 1 mg/kg (administered intraperitoneally) also showed similar effects (Indra et al. [@CR95]). Although nantenine had a similar effect with ketanserin, the doses of nantenine used were significantly larger than that of ketanserin. Additionally, nantenine (20--50 mg/kg, administered intraperitoneally) presented anticonvulsant effect in inhibiting pentylenotetrazol and maximal electroshock-induced seizures in rats, whereas nantenine at higher doses (75--105 mg/kg, administered intraperitoneally) has been shown to a convulsant activity appears to be related to inhibition of phosphatase at high doses and cause a decrease in Ca^2+^-influx into cells at low doses (Ribeiro and Leite [@CR195]). Unfortunately, the authors of this study did not perform comparisons using a positive control. Magnoflorine (**49**) (20 mg/kg, administered intraperitoneally) alone enhanced cognition, and co-administration of magnoflorine with scopolamine blocked long-term, but not short-term, memory impairment (Kukula-Koch et al. [@CR113]). However, no explanation of the active principle or mechanisms of action was provided and use of a positive control was lacking. Stepholidine (**57**) (2.5, 5.0 and 10 mg/kg, administered intraperitoneally) is a natural dopamine (D) receptor D1 agonist and D2 antagonist. It can significantly reduce cue-induced reinstatement of cocaine seeking, in a dose-dependent manner, and significantly decreased break points for cocaine reward (Manuszak et al. [@CR169]). It is a pity that this trial lacked a positive control. The in vivo effects of stepholidine are largely mediated through blockade of the dopamine receptor with potential cross-talk to other receptors or signaling proteins (Meade et al. [@CR171]). Stepholidine (1, 3 and 10 mg/kg, administered intraperitoneally) has been shown to dose-dependently attenuate reinstatement of a desire to seek 3, 4-methylenedioxypyrovalerone following priming by a cue plus 3, 4-methylenedioxypyrovalerone in an intravenous self-administration model (Hicks et al. [@CR78]). Anyhow, it is important that an experimental animal model is also established to further verify the effects of stepholidine in vivo.

Cardiovascular activity {#Sec26}
-----------------------

### Antihypertensive effects {#Sec27}

*S. tetrandra* has traditionally been used as an antihypertensive and antiarrhythmic treatment. In anesthetized rats, extracts of *S. tetrandra* (50 or 150 mg/kg/day, administered orally) reduced both frequency of arrhythmias and size of infarcts induced by myocardial ischemia and reperfusion. These effects were comparable to those of tetrandrine (50 mg/kg/day) and verapamil (Yu et al. [@CR291]). In this study, phytochemical analysis of extracts of *S. tetrandra* was not evaluated. Moreover, only two doses of extracts of *S. tetrandra* were used throughout this study, limiting any data on dose-dependency. Intragastric administration of tetrandrine (**9**) (30 and 60 mg/kg/day) significantly lowered the blood pressure of spontaneously hypertensive rats by inhibition of the noradrenergic system, rather than by calcium channel blockade. The effects of tetrandrine at the dose of 60 mg/kg/day were similar to those treated with amlodipine (a positive control, 100 mg/kg/day) after one day. After treated with drugs on two and three days, the effects of tetrandrine (30 and 60 mg/kg/day) were weaker than those of amlodipine (100 mg/kg/day) (Huang et al. [@CR91]). Nonetheless, only two doses of tetrandrine were used throughout this study, limiting any data on dose-dependency, as well as the trial lacked a positive control and toxicity assessment. A similar study also reported that intragastric administration of tetrandrine (100 mg/kg, administered orally) significantly lowered the blood pressure of spontaneously hypertensive rats over three days of treatment (Zhang et al. [@CR304]). However, this investigation was also conducted without the use of a positive control and lacked any analysis of a dose-dependent relationship. And the dose of tetrandrine was used too high to provide reliable experimental data for clinical application. Tetrandrine (80 mg/kg/day, administered intraperitoneally) was shown to prevent monocrotaline-induced pulmonary arterial hypertension in rats by regulation of protein expression in inducible NOS and cyclic guanosine monophosphate (cGMP)-dependent protein kinase type 1. Compared with vardenafil (2.0 mg/kg/day, administered intraperitoneally), tetrandrine (80 mg/kg/day) exhibited similar effects against monocrotaline-induced pulmonary arterial hypertension in rats (Wang et al. [@CR252]). The flaws of the study lie in only a single dose of tetrandrine used throughout the study, limiting analysis of dose-dependency. Finally, tetrandrine substantially lowered intraocular pressure in a rat model of ocular hypertension, although no explanation of the active principle or mechanism of action was offered. More importantly, this study did not state the unit of tetrandrine dose, it was just indicated that 0.1%, 0.2%, 0.3% tetrandrine were administered in this study (Huang et al. [@CR88]). Tetrandrine (2.0--20 mg/kg, administered intravenously) has been shown to lower portal venous pressure, mean arterial pressure and total peripheral resistance in cirrhotic rats (Huang et al. [@CR87]). It is worth noting that this study also did not include a positive control or investigate the mechanism of action.

Tetrandrine and fangchinoline inhibited high K^+^ (65.4 mM) and induced sustained contraction in the rat aorta smooth muscle strips, also inhibited 1.0 μM norepinephrine-stimulated Ca^2+^ influx in rat aorta strips. Meanwhlie, tetrandrine (3 mg/kg) and fangchinoline (30 mg/kg) administered by intravenous (i.v.) bolus injection lowered the mean arterial pressure significantly during the period of observation in conscious stroke-prone spontaneously hypertensive rats, respectively. These results showed that tetrandrine was more potent than fangchinoline in blocking calcium channels and antihypertensive activity (Kim et al. [@CR105]). The main limitations of most of these studies lacked positive controls.

Dicentrine (**39**) (3--10 μM) was found to be a potent α~1~-adrenoceptor inhibitor in rat thoracic aortas, as revealed by competitive antagonism of norepinephrine- and phenylephrine-induced vasoconstriction (Teng et al. [@CR228]). Anyhow, the mechanism by which this activity occurred should be investigated further. Oral administration of dicentrine (5 and 8 mg/kg) to conscious spontaneously hypertensive rats induced hypotension that lasted for more than 15 h. Additionally, administration of dicentrine (0.1, 0.5 or 1.0 mg/kg) and prazosin (0.01, 0.05 or 0.1 mg/kg) intravenously induced a dose-related reduction of mean arterial pressure (MAP) which reached a maximal effect 5--10 min after injection and persisted for 2 h. This suggests that dicentrine may have therapeutic potential as an oral or intravenous antihypertensive drug by acting as a blockade of the α-adrenoceptor (Yu et al. [@CR286]). Nonetheles, future studies should attempt to identify the mechanism of action and toxicity of dicentrine. These results reinforce the traditional uses of *S. tetrandra* as an antihypertensive and antiarrhythmic treatment.

### Cardiovascular effects {#Sec28}

The cardioprotective and antiarrhythmic effects of the *S. tetrandra* extract at the concentration of 16.8 μg/ml are equivalent to those of tetrandrine (18.7 μg/ml) alone and either may be a better treatment choice than classical calcium channel antagonists, verapamil, for the treatment of arrhythmia or myocardial infarction induced by ischemia and reperfusion injury (Yu et al. [@CR290]; Wong et al. [@CR259]). In these studies, phytochemical analysis of *S. tetrandra* extracts was not investigated. Moreover, only a single dose of *S. tetrandra* extract and tetrandrine were used throughout the studies, and thus limited the information on the dose-dependent effect. Tetrandrine (**9**) not only acts as an antihypertensive drug, it (50 mg/kg, administered orally) also reverses cardiac and vascular remodeling. The latter occurs through inhibition of vascular smooth muscle cell proliferation, through the inhibition of induction and sensitization of vascular smooth muscle cells to stimulate pro-apoptosis and by improving endothelial function (Rao [@CR191]). Nevertheless, these results did not display a dose-dependent relationship and some investigations lacked positive controls. Renovascular hypertensive rats demonstrated hypertrophy and altered remodeling of the artery and arteriole walls in addition to the proliferation of vascular smooth muscle cells in renal arterioles. This vascular remodeling was shown to be suppressed by tetrandrine (50 mg/kg, administered orally), markedly attenuating these changes (Li et al. [@CR127]), and inhibiting collagen synthesis and deposition in their arteries (Li et al. [@CR126]). However, these studies had important limitations---only one dose of tetrandrine was used and thus no information about dose-dependency was investigated, as well as no appropriate positive controls were used. Tetrandrine (10, 20 or 40 μM) has been shown to antagonize angiotensin II-induced cardiomyocyte hypertrophy by decreasing angiotensin II-induced elevation of pulse rate, cell size, total protein content and rate of protein synthesis. It also inhibited the activity and expression of phosphorylated extracellular regulated kinase1/2 (p-ERK1/2) (Zhou et al. [@CR317]). Unfortunately, the authors of this study did not perform comparisons using a positive control. Furthermore, tetrandrine (15 mg/kg) offered full protection against myocardial infarction that was experimentally induced by non-invasive treatment with isoproterenol in rabbits (Pinelli et al. [@CR187]). The major limitation of this study was the lack of analysis of a dose-dependent relationship. Tetrandrine (0.1 and 1.0 mg/kg) has also been shown to ameliorate ischemic-reperfusion injury in rat myocardium by inhibition of neutrophil priming and activation (Shen et al. [@CR206]). Nevertheless, only two doses of tetrandrine were used in these studies, and thus information regarding the dose-dependent effect is limited.

Dicentrine (**39**) (1, 3 or 9 μM), is equaliate to quinidine (from 0.5 to 4.5 μM), shows promise as an antiarrhythmic agent with type Ia and type III antiarrhythmic action (Young et al. [@CR284]). Dicentrine has the potential to reduce two major cardiovascular risk factors, hypertension and hyperlipidemia. It does this via a decrease in mean arterial pressure and reduced vascular hyperreactivity to phenylephrine. Dicentrine (5 and 10 mg/kg, administered orally) also lowers blood concentrations of cholesterol, low density lipoprotein cholesterol, total plasma triglycerides and very low density lipoprotein cholesterol while increasing concentrations of high density lipoprotein cholesterol (Yu et al. [@CR288]). These experiments had a number of shortcomings, including the absence of a positive control and only two doses of drug, resulting in the lack of reliability of results and absence of analysis of a dose-dependent effect. In anesthetized normotensive rats, acute intravenous administration of nantenine (**44**) (3--5 mg/kg, administered intravenously) produced a dose-dependent decrease in mean arterial pressure, accompanied by a significant decrease in heart rate (Orallo [@CR183]). Nonetheless, future studies should attempt to replicate this effect under clinical conditions using a low dose suitable for human administration.

Stephenanthrine (**65**) (0.01--1.0 μM) is of potential therapeutic interest due to the control of leukocyte recruitment involving angiotensin-II that occurs in cardiovascular disease. Stephenanthrine inhibits angiotensin-II-induced endothelial P-selectin upregulation. It also inhibits ROS generation in endothelial cells stimulated by angiotensin-II in both *N*-formylmethionyl-leucyl-phenyl-alanine (fMLP)-stimulated human neutrophils and in the hypoxanthine-xanthine oxidase system (Estellés et al. [@CR55]). However, it should be noted that this study also did not include a positive control.

### Immunomodulatory effects {#Sec29}

Extracts of *S. tetrandra* and its principal active components, tetrandrine (**9**) and fangchinoline (**10**), have been used to treat autoimmune diseases, such as rheumatoid arthritis, transplant rejection and systemic lupus erythematosus (Semwal et al. [@CR202]; Lai [@CR115]; Sekiya et al. [@CR201]; Seow et al. [@CR203]). Rheumatoid arthritis patients were administered 10 g extract of *S. tetrandra* orally for 12 weeks in a clinical trial. The clinical trial results showed that extract of *S. tetrandra* could significantly reduce the lipid peroxide level, the plasma human granulocyte elastase level, granulocyte count and proportion of granulocytes in peripheral blood of rheumatoid arthritis patients, and increase leukocyte/elastase ratio and granulocyte/elastase ratio (Sekiya et al. [@CR201]). The limitations of this study were the lack of description of doses and a positive control. Tetrandrine at 0.1--100 μM inhibited neutrophil-monocyte chemotactic factor-1 upregulation and adhesion to fibrinogen induced by N-formyl-methionyl-leucylphenylalanine and phorbol 12-myristate 13-acetate, and reduced production of oxygen free radical, down-regulated synthesis and release of some proinflammatory cytokines (Semwal et al. [@CR202]). In an in vitro study, tetrandrine at 16.0 μM had potent immunosuppressive activity by suppressing the antibody synthesis by B cells, and the mitogen-induced lymphoproliferative response (Seow et al. [@CR203]). Nonetheless, the same shortages of this study as most of the aforementioned literature are lack of positive control and a single dose was used. The underlying mechanisms for these immunomodulatory effects have been studied extensively. These compounds inhibited activation of human peripheral blood T-cells by both phorbol 12-myristate 13-acetate (PMA) + cluster of differentiation 28 (CD28)-costimulation and CD3 + CD28-costimulation (Lai et al. [@CR116]). They have also been shown to reverse the pathological process of collagen-induced arthritis by modulating metabolic pathway imbalances (Yun et al. [@CR294]), markedly alleviating the severity of arthritis and reducing serum concentrations of pro-inflammatory cytokines. The compounds further restored the ratio of T helper 17 (Th17)/ regulatory T (Treg) cells. This has been demonstrated by measurement of serum concentrations of relevant cytokines (IL-17 and IL-10) and the proportion of each cell type (Yuan et al. [@CR293]). They have also reduced expression of Rac family small GTPase 1 (Rac1), cell division cycle 42 (Cdc42) and Ras homolog family member A (RhoA), and inhibited Akt and JNK activation, resulting in the subsequent down-regulation of MMP-2/9, F-actin and FAK activation and/or expression (Lv et al. [@CR162]). They have also been shown to reduce the concentrations of ROS, TNF-α, IL-6, prostaglandin-E2 and matrix metalloproteinases (Shan et al. [@CR205]), and inhibit the secretion of IL-1α, TXB (2), ET-1 and E-selectin in LPS-induced endothelial cells (Hu et al. [@CR84]).

It has also been reported that tetrandrine (20 mg/kg, administered orally of three times a day) exhibits synergistic effects towards rheumatoid arthritis when used in combination with leflunomide or methotrexate in two clinical trials (Zhang et al. [@CR311]; Zhang [@CR296]). Although there are numerous studies of the immunomodulatory effects of tetrandrine and fangchinoline, future studies should attempt to replicate these immunomodulatory effects with appropriate postive controls, and under clinical conditions with low doses suitable for human administration. Neuromyelitis optica is a severe neurological demyelinating autoimmune disease that affects the optic nerves and the spinal cord. Isotetrandrine (**27**) at 100 μM has been shown to reduce astrocyte cytotoxicity in neuromyelitis optica by blocking the binding of neuromyelitis optica-immunoglobulin G (NMO-IgG) to aquaporin 4 (Sun et al. [@CR223]). However, the authors of this study did not perform comparisons using a positive control, as well as conducted only one too high concentration.

Traditionally, *S. tetrandra* has the ability to treat rheumatoid arthritis. Although tetrandrine has been approved in China for its treatment, the immunosuppressive activity, mechanism of action and structure--function relationships of the other constituents in *S. tetrandra* require additional study.

Antifibrotic effects {#Sec30}
--------------------

### Antifibrotic effects in pulmonary disease {#Sec31}

Silicosis is a representative fibrotic pulmonary disease. Tetrandrine (**9**) modulates TNF and collagen gene expression and could be used to treat silicosis alone or in combination with other therapies (Idec-Sadkowska et al. [@CR94]; Liu et al. [@CR149]; Xv and Zhou [@CR273]; Chen et al. [@CR35]; Resit et al. [@CR193]; Castranova et al. [@CR20]). Tetrandrine (50 mg/kg, administered orally) was shown to inhibit the development of experimental silicosis of rats by reducing α~1~ (I) and α~1~(III) collagen mRNA levels of silicotic rat lung, but this study was conducted without the use of positive control, and also lacks analysis of dose-effects relationship of tetrandrine (Idec-Sadkowska et al. [@CR94]; Liu et al. [@CR149]). In a clinical trial, silicosis patients were administered 40 mg tetrandrine orally at three times a day for 6 month. The results of this trial showed that tetrandrine could significantly relieve the clinical symptoms and inhibit pulmonary fibrosis in the treatment of silicosis patients compared with the control group (Xv and Zhou [@CR273]). In another clinical trial, tetrandrine (100 mg, administered orally) combined with ursolic acid was significantly superior to the simple medicine group (only tetrandrine group or only ursolic acid group) (Chen et al. [@CR35]). Nevertheless, these clinical trials have the same shortages of no positive control and absence of dose-effects relationship. Moreover, these studies lacked the safety evaluation of tetrandrine on silicosis patients. The mechanisms governing the antifibrotic action of tetrandrine (2--10 μM) were shown to be inhibit the ability of fibroblasts to respond to stimulation by growth factors, such as platelet derived growth factor, fibroblast growth factor, tumor necrosis factor (Resit et al. [@CR193]). Additionally, tetrandrine (96 μM) could inhibit particle-stimulated oxygen consumption, superoxide release, and hydrogen peroxide secretion by alveolar macrophages, and also exhibited substantial binding affinity for membrane lipids and alveolar macrophages (Castranova et al. [@CR20]). Although tetrandrine has been approved in China for the treatment of silicosis, the antifibrotic effects, mechanisms of other alkaloids in *S. tetrandra*, and toxicity of these alkaloids require further investigation.

### Antifibrotic effects in liver disease {#Sec32}

Extracts of *S. tetrandra* (200 mg/kg) have been demonstrated to safely and effectively prevent and reverse hepatic fibrosis by activating hepatic stellate cell apoptosis in rats (Chor et al. [@CR44]). Nevertheless, the experiment had some shortages, including no positive control and a single dose of drugs, resulting in lower reliability and absence of dose-dependent effect. More importantly, the dose of extracts of S. tetrandra used in the study was too high, and it cannot provide reliable experimental data for clinical application. Furthermore, the extracts tested were not chemically analyzed. Tetrandrine (**9**) (0.39--50 μM) exerted antifibrotic effects in hepatic stellate cells and in rats with hepatic fibrosis in a dose-dependent manner. It achieved this by regulating transforming growth factor-β-activated kinase 1 (TAK1), JNK and NF-κB. It also reduced fibrosis-related gene transcription, attenuated NF-κB-activated pathways and induced metallothionein gene transcription (Li et al. [@CR135]; Hsu et al. [@CR81]; Park et al. [@CR185]). Yet some investigations lacked use of positive controls.

### Other antifibrotic effects {#Sec33}

Tetrandrine (**9**) at 1.0 or 5.0 μM was shown to reverse human cardiac myofibroblast activation and myocardial fibrosis through calcium channel blockade (Teng et al. [@CR229]). However, this study lacked use of a positive control. Tetrandrine (8.0 μM) also exerted an antifibrotic effect on human hypertrophic scar fibroblasts by inducing the expression of microRNA, transforming growth factor-β1 (TGF-β1), SMAD family member 2 (Smad2) and SMAD family member 7 (Smad7) (Ning et al. [@CR179]). Tetrandrine (4.0--20.0 μM) could inhibit human hypertrophic scar fibroblasts at least partially through induction of Smad7 and decrement of Smad2 resulting in inhibition of TGF-b1 transcription and its intracellular signaling, which led to reduction of type I and III collagen production and suppression of cell reproductive activity (Li et al. [@CR130]). Nevertheless, the mechanism of the antifibrotic effect on human hypertrophic scar fibroblasts in vivo requires further study. Additionally, tetrandrine (5 mg/kg/day or 10 mg/kg/day or 20 mg/kg/day) exhibited a synergistic effect when used with prednisone (10 mg/kg/day) for renal fibrosis caused by adriamycin in rats. This was mediated by inhibition of fibrotropic factors and expression of connective tissue growth factor (CTGF) mediated by the promotion of anti-fibrosis factor MMP13 expression (Bai and Dong [@CR7]). We believe that safety and efficacy data should be established next especially via toxicity study prior to entering the human study.

Antidiabetic effects {#Sec34}
--------------------

Tetrandrine (**9**) at 10 mg/kg or 20 mg/kgwas shown to greatly improve the pharmacokinetics and hypoglycemic effects of berberine by inhibiting P-glycoprotein (Shan et al. [@CR204]). Nonetheless, only two doses of tetrandrine were used in this study and thus a full analysis of dose-dependent effects was not possible. Tetrandrine (1 mg/kg, administered intravenously) also activated nicotinic receptors in the adrenal medulla that enhanced the secretion of β-endorphin, and it stimulated opioid *μ*-receptors that increased glucose utilization and/or reduced hepatic gluconeogenesis, lowering plasma glucose concentrations in streptozotocin-induced diabetic rats (Hsu et al. [@CR80]; Chen et al. [@CR26]). A study design with only one dose of drug and an absence of a positive control were definite shortcomings in these studies. Fangchinoline (**10**) (0.3--3 mg/kg) decreased high blood glucose concentrations in a dose-dependent manner and also increased low blood insulin concentrations in streptozotocin-induced diabetic mice (Ma et al. [@CR164]; Tsutsumi et al. [@CR235]). It is unfortunate that these trials lacked proper positive controls, compromising the quality of the studies. Furthermore, fangchinoline (3.0 mg/kg) protected against nephron damage by attenuating changes in the p38 MAPK pathway that reduced oxidative stress and inflammation in rats with diabetic nephropathy (Jiang et al. [@CR98]). Nonetheless, only a single dose of fangchinoline was used in the study, limiting the data on a dose response. Cepharanthine (**25**) (10 mg/kg/day, administered intraperitoneally) was shown to decrease blood and serum concentrations of glucose, urea nitrogen, malondialdehyde and creatinine. It also reduced proteinuria and the kidney to body weight ratio by inhibiting the activation of NF-κB and NLRP3 (Samra et al. [@CR199]). Nevertheless, this investigation was conducted without the use of a positive control and also lacked analysis of the relationship with dose. Treatment with fangchinoline (**10**) (0.3--3.0 mg/kg), fangchinoline 2′-*N*-*α*-oxide (**18**) (1.0 mg/kg) and 2′-*N*-norfangchinoline (**19**) (1.0 mg/kg) reduced elevated blood glucose concentrations to almost half of their initial concentration. In addition, tetrandrine 2′-*N*-*β*-oxide (**15**) (1.0 mg/kg), tetrandrine 2′-*N*-*α*-oxide (**16**) (1.0 mg/kg), tetrandrine 2-*N*-*β*-oxide (**17**) (1.0 mg/kg) and fangchinoline 2′-*N*-*α*-oxide (**18**) (1.0 mg/kg) also decreased hyperglycemic blood concentrations by \~ 50% (Tsutsumi et al. [@CR235]). However, this study lacked appropriate positive controls, compromising the quality of data. Furthermore, the relationship between the structure of those compounds and anti-hyperglycemic effects has not been investigated. Though various constituents in *S. tetrandra* have been evaluated for their anti-hyperglycemic activity, further research is required to verify the effectiveness of the constituents, the mechanisms involved and effective doses. Also, further investigation in both in vivo and in vitro models is required.

Antiplatelet effects {#Sec35}
--------------------

Tetrandrine (**9**) with IC~50~ value of 28.6 ± 3.24 μM and fanchinoline (**10**) with value of IC~50~ 21.7 ± 2.61 μM are known to suppress thromboxane A2 formation, inhibiting platelet aggregation and thrombosis formation (Kim et al. [@CR106]). Flaws in the studies lie in the lack of a positive control. *N*-methylcoclaurine (**1**) at 334.4 μM and coclaurine (**3**) at 350.8 μM have shown strong inhibition of arachidonic acid-induced platelet aggregation (Chen et al. [@CR22]). Yet this investigation was also conducted without the use of a positive control and also lacked analysis of a dose--effect relationship of the two compounds. Moreover, no discussion of the principle of their activity or mechanism of action in vivo was provided, and the concentrations of *N*-methylcoclaurine and coclaurine used were too high to provide reliable experimental data for clinical application. Dicentrine (**39**) (30--150 μM) can inhibit thromboxane formation and increase cyclic AMP concentrations in rabbit platelets. Thus, it offers therapeutic potential as an antiplatelet agent (Yu et al. [@CR287]). Although the study reported on the effects of dicentrine on antiplatelet effects in vitro, they are insufficiently detailed. An experimental animal model should also be established to further verify the antiplatelet effects of dicentrine.

Miscellaneous uses {#Sec36}
------------------

Tetrandrine (60 and 120 mg/kg) has shown great potential in the prevention and treatment of noise-induced hearing loss. It acts primarily by preventing outer hair cell damage and preventing synapse loss between inner hair cells and spiral ganglion neurons (Yu et al. [@CR292]). Despite the dramatic effects of tetrandrine in protection against noise-induced hearing loss at the cellular level, molecular mechanisms underlying this protection are not well understood. Tetrandrine at 10 μM had strong anti-adipogenic effects on 3T3-L1 pre-adipocytes. These effects are possibly largely attributed to a reduction in the expression and/or phosphorylation of CCAAT/enhancer-binding protein-α (C/EBP-α), peroxisome proliferator-activated receptor-γ (PPAR-γ), fatty acid synthase (FAS), perilipin A and signal transducer and activator of transcription-3 (STAT-3) (Jang [@CR97]). Nonetheless, important issues still require resolution, including the antiadipogenic effect of tetrandrine on obese animal models.

Tetrandrine (0.6, 2.0 or 6.0 mg/kg) prevented bone loss in sciatic-neurectomized mice by inhibiting receptor activation of NF-κB ligand-induced osteoclast differentiation (Takahashi et al. [@CR224]). We believe that further work will be required to clarify that tetrandrine acts on the expression and/or function of transcription factors which form complexes with the nuclear factor of activated T cells c1 (NFATc1) in osteoclasts. Tetrandrine (10, 30 or 100 μM) was demonstrated to relax corpus cavernosum tissues in rabbits. This was attributed to the inhibition of extracellular Ca^2+^ influx and suppression of intracellular-stored Ca^2+^ release, but it was not mediated by NO, prostaglandin release or potassium channel activation (Chen et al. [@CR28]). However, further experiments are required to establish whether the cAMP or Rho-A/Rhokinase pathways contribute to tetrandrine-induced relaxation. Tetrandrine at the concentration of 3.2 μM has radioprotective effects against 10 Gy of ionizing irradiation and it was able to suppress irradiation-induced inflammatory processes (Chen et al. [@CR23]). However, this study had some shortcomings, including lack of a positive control and exploration of only a single dose of drug, resulting in lower reliability of data and absence of any investigation of a dose--response effect.

Tetrandrine (15, 30 or 60 mg/kg, administered intraperitoneally) and fanchinoline (30 or 60 mg/kg, administered intraperitoneally) were shown to dose-dependently modulate serotonergic function and antagonize morphine-induced analgesia dependent on serotonergic mechanisms (Zhang and Fang [@CR297]; Fang et al. [@CR59]). Though these studies suggested that antagonism of morphine-induced antinociception by tetrandrine was dependent on serotonergic mechanisms, the precise domain of action on the serotonergic system requires further clarification. Reticuline (**5**) (IC~50~ 474 μM) and coclaurine (**3**) (IC~50~ 68.9 μM) have demonstrated antispasmodic activity related to either inhibition of extracellular calcium, an intracellular effect, or both (Martin et al. [@CR170]). Yet the IC~50~ values of reticuline and coclaurine were too high to provide reliable experimental data for clinical application. Moreover, that study merely evaluated the antispasmodic activity of reticuline and coclaurine, their mechanisms of action in vivo requiring further investigation.

Tetrandrine is a classic calcium channel inhibitor involved in various activities (Wang and Lemos [@CR241]; Wang et al. [@CR244]; Leung et al. [@CR123]). In rat phaeochromocytoma PC 12 cells, 100 μM tetrandrine abolished high K^+^ (30 mM)-induced sustained increase in cytoplasmic Ca^2+^ concentration, inhibited bombesin-induced inositol triphosphate accumulation in NIH/3T3 fibroblast and abolished Ca^2+^ entry (Takemura et al. [@CR225]). The shortage of this study was that the dose of tetrandrine was too high and only one dose was used. Tetrandrine (3--100 μM) concentration and time dependently inhibited the amplitude of the \[Ca^2+^\]~i~ transient without any significant effect on the resting level of \[Ca^2+^\]~i~ in the isolated single rat cardiomyocyte (Wang et al. [@CR243]). Tetrandrine (10--30 μM) significantly inhibited the increase of \[Ca^2+^\]~i~ in induced by glutamate, serotonin and histamine in dissociated retina cells (Xuan et al. [@CR271]). 30 μM tetrandrine inhibited NO production by the endothelial cells through blockade of Ca^2+^ release-activated Ca^2+^ channels (Kwan et al. [@CR114]). Tetrandrine inhibited Ca^2+^-activated chloride channel in cultured human umbilical vein endothelial cells with an IC~50~ of 5.2 ± 0.4 μM (Fang et al. [@CR58]). Fangchinoline (0.1--10 μM), a nonspecific Ca^2+^ channel blocker, mitigated the harmful effects of cyanide-induced neuronal cell death by interfering with \[Ca^2+^\]~i~ influx by inhibiting glutam ate release and oxidants generation(Cho and Seong [@CR40]). Some experimental animal models must be established to further verify these effects in vivo.

Tetrandrine (60--120 μmol/L) decreased Na^+^ current density in a concentration-dependent manner and made the voltage-dependent activation curve shift to more positive voltages in the atrial myocardium of patients in atrial fibrillation and sinus rhythm (Chen et al. [@CR29]). Large-conductance K^+^ channel is a target for therapeutic strategies aimed at modulating osteoblast proliferation and function. Tetrandrine (5--30 μM) could inhibit large-conductance K^+^ channel in MG63 cells and primary human osteoblasts (Henny et al. [@CR77]). But these studies lacked proper positive controls.

Cepharanthine (**25**) (0.0625--2.0 μM) can inhibit receptor activation of osteoclast formation and bone-resorbing activity induced by either NF-κB ligand or estrogen deficiency. Thus, it could be potentially used as an alternative therapy for preventing or treating osteolytic diseases (Lin et al. [@CR146]; Zhou et al. [@CR319]). However, these authors did not compare the efficacy of cepharanthine with a positive control. Isotetrandrine (**27**) (8, 16 or 32 μM) ameliorates tert-butyl hydrogen peroxide-induced oxidative damage through the upregulation of heme oxygenase-1 expression. This occurred through the dissociation of nuclear translocation of factor-erythroid 2 p45-related factor 2 (Nrf2) from the Nrf2-Keap1 complex by activation of extracellular signal-regulated protein kinase and c-Jun NH2-terminal kinase, and by inactivation of Keap1 (Wang et al. [@CR251]). The major limitation of this study was the lack of a positive control. Dicentrine (**39**) (0.03--0.3 μM) causes a blockade of the α~1~-adrenoceptor. It has therapeutic potential for relieving bladder outlet obstruction caused by benign prostatic hyperplasia (Yu et al. [@CR289]). Since only in vitro isometric tension experiments were studied, an experimental animal model should also be established to further verify the effectiveness of relief of bladder outlet obstruction.

In addition, at the concentration of 10^−4^ M, tetrandrine (**9**), cepharanthine (**25**), fangchinoline (**10**) and *N*-methylcoclaurine (**1**) have demonstrated potential anti-inflammatory effects through inhibition of the release of histamine. Of these compounds, *N*-methylcoclaurine exhibited an inhibitory effect similar to that of fangchinoline (Nakamura et al. [@CR177]). However, this study evaluated the anti-inflammatory effects of these compounds by inhibition of histamine release only, their mechanisms of action requiring additional investigation. Nantenine (**44**) (0.3 mg/kg, administered intraperitoneally) was shown to block and rapidly reverse hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA), attenuate lethality and reduce MDMA-induced locomotor stimulation and head twitches in mice (Legendre et al. [@CR122]). However, although the study was conducted in an animal model, only one dose was investigated and so additional research is required to further verify its effects. Magnoflorine (**49**) at 53.5 μM in combination with hyaluronic acid gel promoted subchondral bone regeneration. It also exhibited a protective effect by stimulating the recovery of subchondral bone integrity and attenuating cartilage degradation, preventing the progression of osteoarthritis (Cai et al. [@CR19]). However, this study evaluated the potential benefits of hyaluronic acid-gel combined with magnoflorine in promoting subchondral bone regeneration and the protective effects of stimulating recovery of subchondral bone integrity on attenuating cartilage degradation. The effect of magnoflorine without hyaluronic acid-gel should also be evaluated. Magnoflorine (0--10 μM) was also found to inhibit copper-mediated oxidation of low and high density lipoproteins. It also inhibited glycated and glycoxidated low density lipoproteins by increasing the lag time of conjugated diene formation and prevented the generation of thiobarbituric acid reactive substances (Hung et al. [@CR92], [@CR93]). As above, this trial lacked a positive control.

Pharmacokinetics, including metabolism {#Sec37}
======================================

Oral administration of 100 mg of tetrandrine (**9**) in six healthy male volunteers (28--41 years of age) resulted in an area under the curve of plasma concentrations over 0 to infinity (AUC~0→∞~) of 1554.16 ± 25.07 μg.h/L. The time to reach maximum plasma concentration (*T*~max~) was 14.00 ± 10.02 h with a maximum plasma concentration (*C*~max~) of 67.26 ± 23.22 μg/L. The elimination half-life (*t*~1/2~) was 22.34 ± 21.22 h (Yang et al. [@CR274]). In a Sprague Dawley (SD) rat model, there was no statistical difference between males and females in tetrandrine plasma concentrations at identical time points, indicating that no sex differences existed in the pharmacokinetics of tetrandrine in SD rats. The principal pharmacokinetic parameters were as follows: AUC~0→72~ 6279.2 ± 2411.5 μg h/L, AUC~0→∞~ 7002.7 ± 2528.0 μg h/L, *C*~max~ 237.1 ± 95.9 μg/L, *T*~max~ 6.0 ± 1.8 h, *t*~1/2~ 20.6 ± 3.7 h and an elimination rate constant (*K*e) of 0.034 ± 0.006 h^−1^ (Song et al. [@CR218]). After single intravenous dose of 4 mg/kg tetrandrine in rabbits, a biphasic concentration--time curve was observed, essentially conforming to a two-compartment pharmacokinetic model. The *t*~1/2~ of the two-compartments was short at approximately 7.20 min and 92.68 min (Lou and Zhang [@CR157]). A two-compartment pharmacokinetic model and similar pharmacokinetic parameters were also obtained after single intravenous doses of 13 mg/kg tetrandrine to five anesthetized dogs (Zeng et al. [@CR295]).

Although fangchinoline (**10**) has been shown to have various pharmacological properties, there have been few pharmacokinetic studies on this compound. To compare the different pharmacokinetic parameters of tetrandrine (**9**) and fangchinoline, 9.3 g/kg tetrandrine and 3.1 g/kg fangchinoline were administered orally to two groups of rats. With the exception of clearance, the majority of the pharmacokinetic parameters were greater for tetrandrine than for fangchinoline. For example, the *t*~1/2~ of tetrandrine was 49.6 h and 12.273 h for fangchinoline (Li et al. [@CR129]).

The pharmacokinetic parameters of cepharanthine (**25**) in human trials have been reviewed (Desgrouas et al. [@CR49]). After a single oral dose of 50 mg in 12 healthy Chinese volunteers, cepharanthine was rapidly distributed to tissues before being gradually eliminated. It had the pharmacokinetic parameters *C*~max~: 136 ± 67 µg/L; *T*~max~: 0.75 ± 0.21 h and *t*~1/2~: 132 ± 48 h (Hao et al. [@CR73]). A Japanese study indicated a linear relationship between oral administration of doses in the range 25 to 100 mg and measured plasma AUC. Absolute oral availability was low at 6--9%, suggesting extensive pre-systemic liver metabolism. No side effects were reported during the study period (Yasuda et al. [@CR278]). In addition, a recent pharmacokinetic study in rats (Deng et al. [@CR48]) demonstrated poor oral availability of cepharanthine at only 5.65 ± 0.35%. In that study, a single intravenous injection of 1 mg/kg cepharanthine produced a *C*~max~ of 153.17 ± 16.18 µg/L and *t*~1/2~ of 6.8 ± 1.2 h. Oral administration of 10 mg/kg cepharanthine demonstrated poor oral availability, with a *C*~max~ of 46.89 ± 5.25 µg/L of approximately 2.67 h. The *t*~1/2~ was 11.02 ± 1.32 h (Deng et al. [@CR48]).

Two mature female Langyu small-ear miniature pigs were fed 51.3 mg/kg dicentrine (**39**) mesylate (equivalent to dicentrine 40.0 mg/kg). Twenty-four metabolites were identified in the urine collected from the two pigs. These included nine phase I metabolites, including *N*-demethylated dicentrine, *N*-oxidated dicentrine and *O*-demethylated dicentrine. There were also 15 phase II metabolites, *O*-glucuronidation and *O*-glucosylation derivatives of the phenolic groups of the phase I metabolites (Lai et al. [@CR117]). After intravenous administration of 10 mg/kg dicentrine to rats, the detailed pharmacokinetic parameters of dicentrine were measured as: volume of distribution (Vd): 12.58 ± 1.11 L/kg; clearance (CL): 0.51 ± 0.046 L/kg/min; AUC~0→∞~: 20.95 ± 2.28 μg.min/ml; area under the first moment curve (AUMC): 1262 ± 354 μg min^2^/ml; mean residence time (MRT): 55.18 ± 8.52 min (Tsai et al. [@CR234]).

An intravenous dose of 5 mg/kg or an oral dose of 15 mg/kg magnoflorine (**49**) was administered to two groups of male SD rats. The resultant pharmacokinetic evaluation indicated that magnoflorine had a low oral availability of 22.6%. Assessment of the concentration--time curves of magnoflorine in plasma and various tissues (heart, liver, spleen, lung, kidney and brain) after oral administration of 40 mg/kg revealed that it underwent rapid and wide tissue distribution, with the highest concentrations found in the liver, followed by the heart, spleen and lungs. The concentration was least in the brain, indicating that it has difficulty crossing the blood--brain barrier (Bao et al. [@CR11]). After intraperitoneal and oral administration of magnoflorine to rats, the 12 phase I metabolites already identified that were found in various biological matrices (e.g. urine, feces, plasma and organ tissues) were products of demethylation, dehydrogenation, hydroxylation, methylene to ketone transformation, *N*-ring opening and dihydroxylation. The 11 phase II metabolites consisted of products of methylation, acetylation, glucuronidation and *N*-acetylcysteine conjugation (Tian et al. [@CR231]).

The plasma pharmacokinetics and tissue distribution of roemerine (**52**) in rats was evaluated after oral administration of 20 mg/kg or intravenous administration of 6 mg/kg. Significant roemerine concentrations were detected in all tissues examined 5 min after oral administration, with peak concentrations observed after 20 min in all tissues except the liver, where the highest tissue concentrations were found, in addition to in the lungs, then in decreasing order in the kidneys, spleen and heart. This implies that the liver and lungs might be the target organs of roemerine. As roemerine was also detected in the brain, this suggests that it was able to cross the blood--brain barrier (Liu et al. [@CR151]).

Orally administered stepholidine (**57**) was rapidly absorbed in the gastrointestinal tract of SD rats, although the oral availability was poor due to extensive pre-systemic metabolism via glucuronidation and sulfation. There were two concentration peaks of stepholidine in plasma, the second peak potentially resulting from enterohepatic circulation. A total of 17 metabolites of glucuronidated stepholidine and sulphated stepholidine were detected in different tissues. Of note, stepholidine was efficiently transported across the blood--brain barrier (Sun et al. [@CR222]).

After oral administration of 60 mg/kg corydalmine (**60**) to SD rats, the tissue distribution of corydalmine was measured after 0, 0.5, 1, 2, 4, 6, 8, 12, 24 and 48 h post-dose in the brain, heart, kidneys, liver, lungs, spleen, spinal cord and muscle. The results revealed that corydalmine was distributed widely in tissues, although the time to peak concentration varied. Peak concentrations of corydalamine were observed after less than 1 h in the heart, spleen and brain, but after 2--6 h in the kidneys, lungs, spinal cord and muscle. The time to peak concentration occurred after approximately 6 h in the liver, the principle site of corydalamine metabolism by hepatic microsomes. These data indicate that corydalmine was absorbed after oral administration and then distributed quickly in SD rats in vivo. Furthermore, high concentrations in the brain and spinal cord may be related to the pharmacological activity of this compound in the central nervous system (Zhang et al. [@CR310]). Metabolism of L-corydalmine was evaluated in vitro in liver microsomes from five species: mice, rats, monkeys, dogs and humans. Six metabolites, including three *O*-demethylated corydalmines and three hydroxylated corydalmines were identified in all five species (Tang et al. [@CR226]).

Isotetrandrine (**27**) (100 mg/L) was incubated with a male rat hepatic S9 fraction in the presence of a nicotinamide adenine dinucleotide phosphate-generating system. Five metabolites identified were *N*-desmethyl-isotetrandrine, hydroxyl-isotetrandrine, oxo-isotetrandrine, oxohydroxy-isotetrandrine and *N*, *N*-didesmethyl-isotetrandrine (Wu et al. [@CR262]).

The pharmacokinetics and metabolites were evaluated in SD rats administered 30 mg/kg isoboldine (**47**) by oral gavage. Isoboldine was found to have extremely low oral availability due to a strong first-pass effect. The principle metabolic routes for isoboldine were glucuronidation and sulfonation (Li et al. [@CR134]).

Toxicity {#Sec38}
========

Recently, the toxicity of traditional medicines, including TCM, have attracted attention, especially those related to nephrotoxicity caused by aristolochic acids and a number of alkaloids (Xu et al. [@CR270]). To date, no aristolochic acids have been found in *S. tetrandra*. However, confusion surrounding the use and misidentification of TCMs has increased the risk of toxicity. *A. fangchi* can cause nephrotoxicity. Misidentification often occurs between *S. tetrandra* and *A. fangchi,* resulting in inappropriate use and possible toxic effects (Vanherweghem [@CR238]). In addition to nephrotoxicity, traditional herbs may cause toxicity to other organs, including the liver and lungs, in addition to genotoxicity.

Tetrandrine (**9**) has been shown to induce oxidative stress and mitochondrial dysfunction in hepatocytes (Qi et al. [@CR188]; Cai et al. [@CR17]). Tetrandrine has been shown to cause acute pulmonary toxicity. This may be due to its biotransformation to a quinone methide-derived metabolite mediated by cytochrome P450 3A (CYP3A) enzymes (Tian et al. [@CR232]). Tetrandrine has the potential for genotoxicity and carcinogenicity (Rosenkranz and Klopman [@CR196]; Whong et al. [@CR257]; Xing et al. [@CR267]). After intravenous administration of a single dose of 150 mg/kg tetrandrine to mice, tetrandrine induced transient toxicity to the liver, lungs and kidneys. Withdrawal of tetrandrine was associated with reversal of these pathological changes (Shi et al. [@CR209]). Although no nephrotoxicity caused by aristolochic acids has been reported in *S. tetrandra*, it may have the potential to cause nephrotoxicity. After *S. tetrandra* was chronically administered to SD male rats for more than 4 weeks, it damaged tubulointerstitial tissue and damaged the structure of glomeruli (Sun and Wu [@CR220]; Cai et al. [@CR16]). However, as described above, tetrandrine used in combination with prednisone caused a synergistic effect on renal fibrosis caused by adriamycin in rats (Bai and Dong [@CR7]). Therefore, a safe and effective dose of tetrandrine still requires evaluation.

Of the compounds in *S. tetrandra*, only tetrandrine has been reported to have the potential for hepatotoxicity, pulmonary toxicity, genotoxicity or nephrotoxicity. The toxicity of other structurally similar compounds in *S. tetrandra* requires further evaluation.

Conclusions, discussion and future perspectives {#Sec39}
===============================================

The present review summarized the research progress in the traditional use, phytochemistry, pharmacology and toxicology of *S. tetrandra* and its extracts and constituents. The research achievements and gaps were discussed. Although there have been some achievements in the traditional use, phytochemistry, pharmacology and toxicology of *S. tetrandra*, there are still some scientific gaps. Theses scientific gaps are as follows: (1) the plant origin of "Fang Ji" and the strating time of traditional uses of *S. tetrandra* is needed to further investigation. (2) Lack of phytochemistry studies on the aerial part of *S. tetrandra*. (3) Anti-inflammatory and anticancer effects are the most studied in the wide range of pharmacological properties of *S. tetrandra*. However, other pharmacological properties need to further in-depth investigated *S. tetrandra*. (4) Toxicological studies on *S. tetrandra* are limited. To date, only tetrandrine from *S. tetrandra* has been identified as causing potential toxicity to the liver, lungs, genes and kidneys. Due to a lack of data assessing other alkaloids, their toxicity requires further evaluation. (5) There are many alkaloids that have only been tentatively identified by mass spectrometry. Their precise structures need to be determined by an in-depth exploration using nuclear magnetic spectroscopy (NMR), infrared spectroscopy (IR), ultraviolet spectroscopy (UV), circular dichroism (CD) and mass spectrometry (MS). (6) Alkaloids are traditionally considered the major bioactive compounds in *S. tetrandra*, which leads to the result that other constituents of *S. tetrandra* such as bisflavone have not yet been investigated. It severely limited the diversity of research and applications of *S. tetrandra*. (7) Analyses of the structure--activity relationships of these alkaloids are insufficient. (8) In vitro and in vivo pharmacological studies have increasingly confirmed the traditional use of *S. tetrandra* as an analgesic, antiphlogistic and immunoregulatory medicine for arthralgia caused by rheumatism and inflamed sores. However, it's antinociceptive and immunomodulatory effects have been insufficiently studied. (9) Studies on the pharmacology, especially anti-tumor effects, have critical limitations, with insufficient numbers, replications and a lack of in-depth or systematic study at the molecular and cellular levels. (10) *S. tetrandra* has been shown to possess a number of distinct pharmacological activities at both the cellular level and that of the whole organism. However, the mechanisms of action of component molecules are poorly described and require further investigation.

Future perspectivesBased on the traditional uses *S. tetrandra* to treat arthralgia caused by rheumatism and inflamed sores, a greater number of studies of the antinociceptive and immunomodulatory effects should be conducted in future.Most of the compounds studied are those identified in the roots of *S. tetrandra*, and so more studies are required of the chemical constituents of the aerial parts of *S. tetrandra*.The definitive structures of the majority of the alkaloids should be confirmed using comprehensive spectroscopy techniques.The anticancer effects of alkaloids in *S. tetrandra* should be further verified in vivo. Thus, *S. tetrandra* has the potential to be explored as a new anticancer drug.Further in vitro and in vivo animal studies are required for toxicological evaluation prior to future clinical studies.
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